var title_f11_54_12128="Follicular involvement in MF";
var content_f11_54_12128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular involvement in mycosis fungoides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflamed follicular based papules or scale may signal follicular involvement in mycosis fungoides and S&eacute;zary syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12128=[""].join("\n");
var outline_f11_54_12128=null;
var title_f11_54_12129="Paratracheal lymph node CT I";
var content_f11_54_12129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Stage IIIB lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan from a patient with left upper lobe poorly differentiated adenocarcinoma invading the mediastinum. Left panel: Left lower (large arrow) and right lower (small arrow) paratracheal lymph node involvement. Right panel: More caudal view shows tumor encasing the left pulmonary artery (arrow) and the descending aorta (Ao). Enlarged subcarinal lymph nodes are present. These are N3 lymph nodes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12129=[""].join("\n");
var outline_f11_54_12129=null;
var title_f11_54_12130="Sacrocolpopexy";
var content_f11_54_12130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sacrocolpopexy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After dissecting the bladder and rectum off the anterior and posterior vaginal walls, respectively, a Y-shaped graft is sutured to the anterior and posterior endopelvic fascia with a series of permanent sutures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter L Rosenblatt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12130=[""].join("\n");
var outline_f11_54_12130=null;
var title_f11_54_12131="Contact derm eyelids";
var content_f11_54_12131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis of the periorbital skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12131=[""].join("\n");
var outline_f11_54_12131=null;
var title_f11_54_12132="Azelastine (nasal): Patient drug information";
var content_f11_54_12132=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azelastine (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8022?source=see_link\">",
"     see \"Azelastine (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/20/5445?source=see_link\">",
"     see \"Azelastine (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7976934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Astelin&reg;;",
"     </li>",
"     <li>",
"      Astepro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7976935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Astelin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14329068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azelastine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store upright at room temperature. Do not freeze. Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10814 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12132=[""].join("\n");
var outline_f11_54_12132=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976934\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976935\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14329068\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030885\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030884\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030889\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030890\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030892\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030887\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030888\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030893\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030894\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8022?source=related_link\">",
"      Azelastine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/20/5445?source=related_link\">",
"      Azelastine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/47/17139?source=related_link\">",
"      Azelastine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/17/38164?source=related_link\">",
"      Azelastine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31026?source=related_link\">",
"      Azelastine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_54_12133="Bell palsy photos";
var content_f11_54_12133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Bell's palsy: Idiopathic facial nerve (cranial nerve VII) palsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Man with idiopathic peripheral facial nerve (cranial nerve VII) palsy, or Bell's palsy.&nbsp; A) Demonstrates inability to raise the left eyebrow or generate wrinkles on the left side of forehead; B) Demonstrates difficulty closing the left eye and inability to raise the left corner of mouth; C) Demonstrates drooping at the left corner of mouth, loss of the left nasolabial fold, and inability to completely close the left eye.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Charles Goldberg, MD and The University of California, San Diego. Copyright &copy; 2005 The Regents of the University of California. file://medicine.ucsd.edu/clinicalimg/neuro-central-CN7-palsy2.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12133=[""].join("\n");
var outline_f11_54_12133=null;
var title_f11_54_12134="Preoperative autologous blood donation";
var content_f11_54_12134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preoperative autologous blood donation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/54/12134/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/54/12134/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/54/12134/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/54/12134/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/54/12134/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/54/12134/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/54/12134/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative autologous donation (PAD) is the most popular and widely used of the autologous options, which also include preoperative hemodilution and blood salvage. Interest in all forms of autologous transfusion, particularly PAD, mushroomed in response to the AIDS epidemic, beginning as early as 1983. By 1993, when participation in PAD peaked, approximately 6 percent of all blood collected in the United States was collected for autologous use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37684?source=see_link\">",
"     \"Acute normovolemic intraoperative hemodilution\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=see_link\">",
"     \"Intraoperative and postoperative blood salvage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most obvious benefit of PAD for the",
"    <span class=\"nowrap\">",
"     donor/patient",
"    </span>",
"    is freedom from concern about infectivity of the blood. Assuming that the donor is not bacteremic at the time of donation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there are no clerical errors resulting in the inadvertent transfusion of the wrong unit of blood, the patient is also protected against hemolytic, febrile or allergic transfusion reactions; alloimmunization to erythrocyte, leukocyte, platelet or protein antigens; and graft-versus-host disease (GVHD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional benefit is that erythropoiesis may be stimulated by repeated phlebotomies, thereby enabling the patient to regenerate hemoglobin at an accelerated rate after surgery.",
"   </p>",
"   <p>",
"    The overall efficacy of PAD has been evaluated in both randomized trials and cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/1\">",
"     1",
"    </a>",
"    ]. A meta-analysis found that patients who underwent PAD were much less likely than controls to receive allogeneic blood (odds ratio 0.17) but were more likely to undergo any transfusion with autologous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allogeneic blood (odds ratio 3.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/2\">",
"     2",
"    </a>",
"    ]. The latter effect is due both to a lower hematocrit in patients undergoing PAD and a more liberal transfusion policy when using autologous blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DRAWBACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAD programs are not without some drawbacks. Perhaps the most important is that autologous blood is considerably more expensive than allogeneic blood. This problem is compounded by the fact that current reimbursement programs (including Medicare) either deny the medical necessity of PAD or ignore the well-documented increase in cost [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basis for the higher cost includes the extra time and attention required by autologous",
"    <span class=\"nowrap\">",
"     donor/patients;",
"    </span>",
"    the enhanced clerical requirements; the special handling (additional labels, separate storage, early delivery to the hospital, etc); and the fact that blood that is not transfused to the intended recipient (approximately 50 percent of donated blood) is generally wasted rather than transfused to other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also the potential, as with any transfusion, both for undetectable bacterial growth during liquid storage, and for clerical error, resulting in the",
"    <span class=\"nowrap\">",
"     donor/patient",
"    </span>",
"    receiving allogeneic blood rather than the predonated autologous units.",
"   </p>",
"   <p>",
"    These concerns take on added significance in light of a study demonstrating that, for patients undergoing elective hysterectomy, PAD was an independent risk factor for requiring a transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/5\">",
"     5",
"    </a>",
"    ]. Transfusions were given to 25 of 140 women who had undergone PAD versus only 1 of 123 who had not. Similar results were obtained in a prospective randomized trial in patients scheduled to undergo hip replacement surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/6\">",
"     6",
"    </a>",
"    ]. Both a higher incidence of anemia due to preoperative blood donation and a more liberal transfusion policy when autologous blood was available are thought to be responsible for this difference. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link\">",
"     \"Controversial areas in preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the late 1980s, when concern about infection risk was at its peak, virtually all patients contemplating surgery who had even a remote necessity for blood transfusion chose to participate in a PAD program. As a result of this overutilization, actual usage of predonated units by autologous",
"    <span class=\"nowrap\">",
"     donor/patients",
"    </span>",
"    declined to between 40 and 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This has led to the generation of guidelines to increase the efficiency of PAD. Good candidates for PAD include patients with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They are in relatively good health.",
"     </li>",
"     <li>",
"      They can tolerate iron replenishment.",
"     </li>",
"     <li>",
"      They are about to undergo a surgical procedure during which the likelihood of blood loss in excess of 500 to 1000 mL is equal to or greater than 5 to 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another approach for the last criterion is to encourage PAD for any patient scheduled for elective surgery for whom crossmatched blood is recommended by the local hospital maximum blood order schedule.",
"   </p>",
"   <p>",
"    The number of units to be predonated depends upon the anticipated blood loss, an amount that varies, even for the same procedure, among surgical teams in different hospitals. It is therefore difficult to make general recommendations regarding the number of units to collect for specific procedures. A method has been proposed to estimate, in a given hospital, the approximate number of autologous units to draw for any procedure in order to prevent the need for allogeneic blood in any given percentage of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/10\">",
"     10",
"    </a>",
"    ]. This method is called SOPCAB, an acronym for \"schedule of optimal preoperative collection of autologous blood.\"",
"   </p>",
"   <p>",
"    SOPCAB, although not widely utilized, is a reasonable first step. One simply calculates, for a given procedure, how much blood would have had to have been predonated in order to satisfy the complete blood needs of 75 percent of patients. That number then becomes the standard order unless there are special circumstances that dictate any changes. The major drawback to this approach is that a great deal of extra blood is drawn and ultimately wasted in order to satisfy the transfusion needs of a large percentage of patients.",
"   </p>",
"   <p>",
"    Virtually any patient deemed medically able to tolerate a surgical procedure involving general anesthesia should also be able to tolerate the withdrawal of one unit of blood (500 mL or proportionately less if the donor weighs under 50 kg [110 lb]). Factors strictly defined for allogeneic donors, including age, weight, sex, and hemoglobin level, are evaluated with greater flexibility for the autologous donor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have documented the ability of even higher risk",
"    <span class=\"nowrap\">",
"     donor/patients",
"    </span>",
"    to tolerate the donation process [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, one report detected a substantial number of adverse hemodynamic changes (systolic and diastolic hypotension, orthostatic hypotension, tachycardia, arrhythmias and ST-T wave changes) not recognized by conventional clinical observation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exclusions from PAD include patients with any of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unstable angina or angina at rest",
"     </li>",
"     <li>",
"      A myocardial infarction within the last three months",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Aortic stenosis",
"     </li>",
"     <li>",
"      Ventricular arrhythmias",
"     </li>",
"     <li>",
"      Transient ischemic attacks",
"     </li>",
"     <li>",
"      Marked hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PAD is also contraindicated in patients with an active infection, particularly if it could be associated with bacteremia. Although most bacteria will not proliferate in the cold, some psychrophilic organisms (such as Yersinia enterocolitica) can reach peak concentrations in blood within one or two weeks of storage at 4&ordm;C. Transfusion of this blood after prolonged cold storage has been associated with fatal reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may also be prudent to discourage PAD in patients over the age of 80. These patients are at minimal risk from conventional transfusions given the current safety of allogeneic blood, and the long latent period before symptoms attributable to a transfusion-transmitted infection typically develop may exceed their life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROGRAM SPECIFICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief review of the sequential steps involved in a PAD program. The controversies involved in the use of PAD, including the extent of testing, release of infectious units, participation by known infectious donors, crossover, the use of erythropoietin, and cost effectiveness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link\">",
"     \"Controversial areas in preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physician request",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are accepted into PAD programs at the request of their clinician, usually the surgeon or anesthesiologist who will perform the surgery. This clinician, or a colleague with credentials in family practice, internal medicine or cardiology, must certify that the phlebotomies pose no undue risk to the patient. The final decision regarding acceptability rests with the medical director of the blood collection facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Iron supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should begin oral iron supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    (or comparable preparation), 300 mg three times per day, if tolerated, as soon as surgery is scheduled. It is preferable to begin this regimen days to weeks before the first phlebotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Scheduling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most practical schedule for obtaining more than one unit of autologous blood is to draw units at weekly intervals, with the last unit drawn at least two weeks, although no fewer than 72 hours, prior to surgery. More intensive donating schedules are possible, but rarely required. Although a last donation 72 hours prior to surgery allows for the volume and protein losses to be replaced, we do not recommend this regimen, since there is no useful purpose served by drawing blood when there is insufficient time for the red blood cells to be replenished.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient considering preoperative autologous donation should not only have an understanding of the risks and benefits of autologous donation and transfusion, but should also be made aware of transfusion alternatives, such as allogeneic blood transfusion and intraoperative cell recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/17\">",
"     17",
"    </a>",
"    ]. Autologous donors should sign an informed consent form prior to donation. This form should outline the advantages, nature, and purposes of autologous transfusion; the risks involved; and the possibility of complications. Permission should also be obtained to share laboratory results with the patient's clinician, if",
"    <span class=\"nowrap\">",
"     indicated.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Donor criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donors/patients",
"    of all ages and weights can participate in PAD programs. For donors weighing less than 50 kg proportionately less blood constitutes one unit as estimated from the following formula [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Amount to draw &nbsp; = &nbsp; 500 mL &nbsp;x &nbsp;(weight [kg] &nbsp;&divide; &nbsp;50)",
"   </p>",
"   <p>",
"    The amount of anticoagulant to leave in the primary container (normally 95 to 102 mL for a full unit) can then be calculated from:",
"   </p>",
"   <p>",
"    &nbsp;Amount of anticoagulant &nbsp; = &nbsp; 95 mL &nbsp;x &nbsp;(amount to draw &nbsp;&divide; &nbsp;500)",
"   </p>",
"   <p>",
"    Blood should only be drawn if the donor's hemoglobin level is at least 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or the hematocrit is at least 33 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Labeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predonated autologous blood must be labeled to reflect all testing that has been done. In addition, a special autologous tag should be attached to the unit. This tag should contain the patient's name, a unique identifying number (eg, social security or hospital registration number), the ABO and Rh group, and the date of expiration of the unit. If incompletely tested or otherwise unsuitable for allogeneic use, the tag must also bear the statement \"for autologous use only &mdash; may not be issued to another patient\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretransfusion compatibility testing can be abbreviated for the autologous",
"    <span class=\"nowrap\">",
"     donor/patient.",
"    </span>",
"    Nevertheless, it is good practice to perform an ABO, Rh and antibody screen on a patient specimen, a confirmation ABO on the autologous unit, and, as a precaution against a clerical or labeling error, an immediate spin crossmatch prior to issuing the unit for transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of autologous blood is not free of potential toxicity including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemolysis secondary to improper handling of the saved units [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sepsis resulting from bacterial contamination of the saved units [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary edema induced by volume overload or transfusion of the wrong unit of blood due to misidentification [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These potential complications make it imperative that autologous blood be transfused wisely and only when specifically indicated. It is never reasonable to transfuse an autologous unit simply because it is available or would otherwise be discarded. Similarly, autologous blood should not be transfused to replace iron, to promote wound healing or general well-being, or to normalize the hemoglobin level. On the other hand, the relative safety of autologous transfusion may permit relaxation of the transfusion \"trigger\" (eg, by transfusing a postpartum patient with a hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;8",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"       \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25491439\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative autologous donation (PAD) is the most popular and widely used of the autologous options, which also include preoperative hemodilution and blood salvage. Interest in all forms of autologous transfusion, particularly PAD, mushroomed in response to the AIDS epidemic, and has substantially diminished now that the safety of blood products has improved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link&amp;anchor=H8#H8\">",
"     \"Laboratory testing of donated blood\", section on 'Infectious disease screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25491459\">",
"    <span class=\"h2\">",
"     Benefits of PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assuming that the donor is not bacteremic at the time of donation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there are no clerical errors resulting in the inadvertent transfusion of the wrong unit of blood, the patient is protected against hemolytic, febrile or allergic transfusion reactions; alloimmunization to erythrocyte, leukocyte, platelet or protein antigens; and graft-versus-host disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Benefits'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25491482\">",
"    <span class=\"h2\">",
"     Drawbacks of PAD",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autologous blood is considerably more expensive than allogeneic blood.",
"     </li>",
"     <li>",
"      There is the potential for bacterial growth during liquid storage, clerical error resulting in the",
"      <span class=\"nowrap\">",
"       donor/patient",
"      </span>",
"      receiving allogeneic blood rather than the predonated autologous units, hemolysis from improper handling of the stored units, volume overload as a result of transfusion, and, rarely, transfusion-related acute lung injury (TRALI) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12134/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In several studies PAD was an independent risk factor for requiring a transfusion. Both a higher incidence of anemia due to preoperative blood donation and a more liberal transfusion policy when autologous blood was available are thought to be responsible for this difference. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Drawbacks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25491619\">",
"    <span class=\"h2\">",
"     Indications and contraindications for PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications and contraindications'",
"    </a>",
"    above)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good candidates for PAD include patients with the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      They are in relatively good health",
"     </li>",
"     <li>",
"      They can tolerate iron replenishment",
"     </li>",
"     <li>",
"      The likelihood of blood loss in excess of 500 to 1000 mL is equal to or greater than 5 to 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exclusions from PAD include patients with any of the following conditions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unstable angina, angina at rest, myocardial infarction within the last three months",
"     </li>",
"     <li>",
"      Heart failure, aortic stenosis, ventricular arrhythmias, marked hypertension",
"     </li>",
"     <li>",
"      Transient ischemic attacks",
"     </li>",
"     <li>",
"      Patients with an active infection, particularly if it is associated with bacteremia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25491432\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that PAD programs currently have marginal value and cost effectiveness. PAD should be restricted to healthy individuals with long life expectancies requiring blood-intensive procedures, or to individuals for whom crossmatch-compatible blood is unavailable (a rare occurrence).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/1\">",
"      Vanderlinde ES, Heal JM, Blumberg N. Autologous transfusion. BMJ 2002; 324:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/2\">",
"      Forgie MA, Wells PS, Laupacis A, Fergusson D. Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red blood cell transfusion: results of a meta-analysis. International Study of Perioperative Transfusion (ISPOT) Investigators. Arch Intern Med 1998; 158:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/3\">",
"      Yomtovian R, Kruskall MS, Barber JP. Autologous-blood transfusion: the reimbursement dilemma. J Bone Joint Surg Am 1992; 74:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/4\">",
"      Fontaine MJ, Winters JL, Moore SB, et al. Frozen preoperative autologous blood donation for heart transplantation at the Mayo Clinic from 1988 to 1999. Transfusion 2003; 43:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/5\">",
"      Kanter MH, van Maanen D, Anders KH, et al. Preoperative autologous blood donations before elective hysterectomy. JAMA 1996; 276:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/6\">",
"      Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am 2002; 84-A:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/7\">",
"      Devine P, Postoway N, Hoffstadter L, et al. Blood donation and transfusion practices: the 1990 American Association of Blood Banks Institutional Membership Questionnaire. Transfusion 1992; 32:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/8\">",
"      Goodnough LT, Saha P, Hirschler NV, Yomtovian R. Autologous blood donation in nonorthopaedic surgical procedures as a blood conservation strategy. Vox Sang 1992; 63:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/9\">",
"      Goldman M, Savard R, Long A, et al. Declining value of preoperative autologous donation. Transfusion 2002; 42:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/10\">",
"      Axelrod FB, Pepkowitz SH, Goldfinger D. Establishment of a schedule of optimal preoperative collection of autologous blood. Transfusion 1989; 29:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/11\">",
"      Mott LS, Bechinski J, Jones MJ. Autologous blood collection in anemic patients using low-dose erythropoietin therapy. J Natl Med Assoc 1997; 89:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/12\">",
"      Nuttall GA, Santrach PJ, Oliver WC Jr, et al. Possible guidelines for autologous red blood cell donations before total hip arthroplasty based on the surgical blood order equation. Mayo Clin Proc 2000; 75:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/13\">",
"      Mann M, Sacks HJ, Goldfinger D. Safety of autologous blood donation prior to elective surgery for a variety of potentially \"high-risk\" patients. Transfusion 1983; 23:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/14\">",
"      Owings DV, Kruskall MS, Thurer RL, Donovan LM. Autologous blood donations prior to elective cardiac surgery. Safety and effect on subsequent blood use. JAMA 1989; 262:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/15\">",
"      Spiess BD, Sassetti R, McCarthy RJ, et al. Autologous blood donation: hemodynamics in a high-risk patient population. Transfusion 1992; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/16\">",
"      Stenhouse MA, Milner LV. Yersinia enterocolitica. A hazard in blood transfusion. Transfusion 1982; 22:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/17\">",
"      Uhl L. Patient blood management: a 68-year-old woman contemplating autologous blood donation before elective surgery. JAMA 2011; 306:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/18\">",
"      Silvergleid AJ. Safety and effectiveness of predeposit autologous transfusions in preteen and adolescent children. JAMA 1987; 257:3403.",
"     </a>",
"    </li>",
"    <li>",
"     Klein HG. Standards for Blood Banks and Transfusion Services. In: American Association of Blood Banks, 16th ed, Bethesda, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/20\">",
"      Cregan P, Donegan E, Gotelli G. Hemolytic transfusion reaction following transfusion of frozen and washed autologous red cells. Transfusion 1991; 31:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/21\">",
"      Richards C, Kolins J, Trindade CD. Autologous transfusion-transmitted Yersinia enterocolitica. JAMA 1992; 268:154.",
"     </a>",
"    </li>",
"    <li>",
"     College of American Pathologists, Comprehensive Transfusion Medicine Survey. Set J-C, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12134/abstract/23\">",
"      Covin RB, Ambruso DR, England KM, et al. Hypotension and acute pulmonary insufficiency following transfusion of autologous red blood cells during surgery: a case report and review of the literature. Transfus Med 2004; 14:375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7930 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12134=[""].join("\n");
var outline_f11_54_12134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25491439\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DRAWBACKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROGRAM SPECIFICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physician request",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Iron supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Scheduling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Donor criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Labeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INDICATIONS FOR TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25491439\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25491459\">",
"      Benefits of PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25491482\">",
"      Drawbacks of PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25491619\">",
"      Indications and contraindications for PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25491432\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37684?source=related_link\">",
"      Acute normovolemic intraoperative hemodilution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=related_link\">",
"      Controversial areas in preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=related_link\">",
"      Intraoperative and postoperative blood salvage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_54_12135="Richters transformation";
var content_f11_54_12135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Richter's transformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node from a patient with chronic lymphocytic leukemia (CLL) undergoing Richter's transformation. The monotonous infiltrate of small lymphocytes on the left side, representing the pre-existing CLL, contrasts with the large B cells on the right, representing transformation to a diffuse large B cell lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12135=[""].join("\n");
var outline_f11_54_12135=null;
var title_f11_54_12136="Doxycycline: Pediatric drug information";
var content_f11_54_12136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxycycline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"    see \"Doxycycline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/10/36005?source=see_link\">",
"    see \"Doxycycline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adoxa&reg;;",
"     </li>",
"     <li>",
"      Alodox&trade;;",
"     </li>",
"     <li>",
"      Doryx&reg;;",
"     </li>",
"     <li>",
"      Doxy 100&trade;;",
"     </li>",
"     <li>",
"      Monodox&reg;;",
"     </li>",
"     <li>",
"      Ocudox&trade;;",
"     </li>",
"     <li>",
"      Oracea&reg;;",
"     </li>",
"     <li>",
"      Oraxyl&trade;;",
"     </li>",
"     <li>",
"      Vibramycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Doxy Tabs&reg;;",
"     </li>",
"     <li>",
"      Apo-Doxy&reg;;",
"     </li>",
"     <li>",
"      Dom-Doxycycline;",
"     </li>",
"     <li>",
"      Doxycin;",
"     </li>",
"     <li>",
"      Doxytab;",
"     </li>",
"     <li>",
"      Novo-Doxylin;",
"     </li>",
"     <li>",
"      Nu-Doxycycline;",
"     </li>",
"     <li>",
"      Periostat&reg;;",
"     </li>",
"     <li>",
"      PHL-Doxycycline;",
"     </li>",
"     <li>",
"      PMS-Doxycycline;",
"     </li>",
"     <li>",
"      Vibra-Tabs&reg;;",
"     </li>",
"     <li>",
"      Vibramycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Tetracycline Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"      see \"Doxycycline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Children &lt;8 years:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anthrax:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     In the presence of systemic involvement, extensive edema, and/or lesions on head/neck, doxycycline should initially be administered I.V. Initial treatment should include two or more agents per CDC recommendations. Agents suggested for use in conjunction with doxycycline include rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, imipenem, clindamycin, or clarithromycin. For bioterrorism postexposure, continue combined therapy for 60 days; if natural exposure, 7-10 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.: 2.2 mg/kg/dose every 12 hours (maximum dose: 100 mg/dose); may switch to oral therapy (same dosing) when clinically appropriate (CDC, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis; postexposure (inhalation or cutaneous): Oral: 2.2 mg/kg/dose every 12 hours for 60 days (maximum dose: 100 mg/dose) (CDC, 2001;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ehrlichiosis:",
"     </b>",
"     Oral, I.V.: 2 mg/kg/dose every 12 hours (maximum dose: 100 mg/dose) for 3 days after defervescence and at least 7 days total (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tickborne rickettsial disease:",
"     </b>",
"     Oral, I.V.: 2.2 mg/kg/dose every 12 hours (maximum dose: 100 mg/dose) for 5-7 days. Severe or complicated disease may require longer treatment; human granulocytotropic anaplasmosis (HGA) should be treated for 10-14 days (CDC, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Children &ge;8 years:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Oral, I.V.: 2-4 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 12-24 hours, maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anthrax (if strain is proven susceptible):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     In the presence of systemic involvement, extensive edema, and/or lesions on head/neck, doxycycline should initially be administered I.V. Initial treatment should include two or more agents per CDC recommendations. Agents suggested for use in conjunction with doxycycline include rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, imipenem, clindamycin, or clarithromycin. For bioterrorism postexposure, continue combined therapy for 60 days; if natural exposure, administer 7-10 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.: 2.2 mg/kg/dose every 12 hours (maximum dose: 100 mg/dose); may switch to oral therapy (same dosing) when clinically appropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis; postexposure (inhalation or cutaneous): Oral: 2.2 mg/kg/dose every 12 hours for 60 days (maximum dose: 100 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Brucellosis:",
"     </b>",
"     Oral: 1-2 mg/kg/dose twice daily for 6 weeks (maximum dose: 100 mg/dose); use in combination with rifampin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chlamydial infections, uncomplicated:",
"     </b>",
"     Oral: 100 mg/dose twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Lyme disease, Q fever, or Tularemia:",
"     </b>",
"     Oral: 100 mg/dose twice daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Oral, I.V.: 2.2 mg/kg/dose twice daily for 7 days (maximum dose: 100 mg/dose) (CDC, 2011); for uncomplicated cases, combination therapy with quinine sulfate is recommended; in severe cases, combination therapy with quinidine gluconate should be used;",
"     <b>",
"      Note:",
"     </b>",
"     Duration of either quinine sulfate or quinidine gluconate is region-specific; consult CDC for current recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: Oral: 2.2 mg/kg/dose once daily (maximum dose: 100 mg/day) starting 1-2 days before travel to the area with endemic infection, continuing daily during travel and for 4 weeks after leaving endemic area; maximum duration of prophylaxis: 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      MRSA, community-acquired cellulitis (purulent); skin/soft tissue infections:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;45 kg: 2 mg/kg/dose every 12 hours for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;45 kg: 100 mg twice daily for 5-10 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tickborne rickettsial disease or Ehrlichiosis:",
"     </b>",
"     &gt;45 kg: Oral, I.V.: 100 mg every 12 hours.  Severe or complicated disease may require longer treatment; HGA should be treated for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adolescents and Adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Oral, I.V.: 100-200 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anthrax (if strain is proven susceptible)",
"     </b>",
"     : Refer to Children's dosing for",
"     <b>",
"      &ldquo;Note",
"     </b>",
"     &rdquo; on route, combined therapy, and duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.: 100 mg every 12 hours for 60 days (substitute oral antibiotics for I.V. antibiotics as soon as clinical condition improves)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis; postexposure (inhalation or cutaneous): Oral: 100 mg every 12 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chlamydial infections, uncomplicated:",
"     </b>",
"     Oral: 100 mg/dose twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Lyme disease, Q fever, or Tularemia",
"     </b>",
"     : Oral: 100 mg/dose twice daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Malaria:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Oral, I.V.: 100 mg twice daily for 7 days (CDC, 2011 ); for uncomplicated cases, combination therapy with quinine sulfate is recommended; in severe cases, combination therapy with quinidine gluconate should be used;",
"     <b>",
"      Note:",
"     </b>",
"     Duration of either quinine sulfate or quinidine gluconate is region-specific; consult CDC for current recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: Oral: 100 mg/dose once daily starting 1-2 days before travel to the area with endemic infection, continuing daily during travel, and for 4 weeks after leaving endemic area; maximum duration of prophylaxis: 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      MRSA, community-acquired cellulitis (purulent):",
"     </b>",
"     Oral: 100 mg twice daily for 5-10 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Nongonococcal urethritis caused by",
"      <i>",
"       C. trachomatis",
"      </i>",
"      or",
"      <i>",
"       U. urealyticum",
"      </i>",
"      :",
"     </b>",
"     Oral: 100 mg/dose twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, inpatient: Oral, I.V.: 100 mg every 12 hours for 14 days administered with cefoxitin or cefotetan; may transition to oral doxycycline (add clindamycin or metronidazole if tubo-ovarian abscess present) to complete the 14 days of therapy (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, outpatient: Oral: 100 mg every 12 hours for 14 days (with or without metronidazole); preceded by a single I.M. dose of cefoxitin (plus oral probenecid) or ceftriaxone (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Periodontitis:",
"     </b>",
"     Oral (Periostat&reg;): 20 mg twice daily as an adjunct following scaling and root planing; may be administered for up to 9 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Rosacea:",
"     </b>",
"     Oral (Oracea&reg;): 40 mg once daily in the morning.",
"     <b>",
"      Note:",
"     </b>",
"     Oracea&reg; capsules are not bioequivalent to other doxycycline products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sclerosing agent for pleural effusion:",
"     </b>",
"     500 mg in 25-30 mL of NS instilled into the pleural space to control pleural effusions associated with metastatic tumors; or for recurrent malignant pleural effusions: 500 mg in 250 mL NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tickborne rickettsial disease or ehrlichiosis:",
"     </b>",
"     Oral, I.V.: 100 mg every 12 hours. Severe or complicated disease may require longer treatment; HGA should be treated for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No adjustment necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oracea&reg;: 40 mg [30 mg (immediate release) and 10 mg (delayed release)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hyclate [strength expressed as base]: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocudox&trade;: 50 mg [kit includes Ocudox&trade; capsules (60s), Ocusoft&reg; Lid Scrub&trade; Plus eyelid cleanser pads, and Tears Again&reg; advanced spray]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oraxyl&trade;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vibramycin&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as monohydrate [strength expressed as base]: 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adoxa&reg;: 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monodox&reg;: 50 mg [DSC], 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hyclate [strength expressed as base]: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doxy 100&trade;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as monohydrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vibramycin&reg;: 25 mg/5 mL (60 mL) [raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as calcium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vibramycin&reg;: 50 mg/5 mL (473 mL) [contains propylene glycol, sodium metabisulfite; raspberry-apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hyclate [strength expressed as base]: 20 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alodox&trade;: 20 mg [kit includes Alodox&trade; tablets (60s), Ocusoft&reg; Lid Scrub&trade; pads, eyelid cleanser, and goggles]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Periostat&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as monohydrate [strength expressed as base]: 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release coated beads, oral, as hyclate [strength expressed as base]: 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release coated pellets, oral, as hyclate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doryx&reg;: 150 mg [scored; contains sodium 9 mg (0.392 mEq)/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule (variable release), powder for suspension, syrup",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer capsules or tablets with adequate amounts of fluid; avoid antacids, infant formula, milk, dairy products, and iron for 1 hour before or 2 hours after administration of doxycycline (unless extemporaneously prepared in the instance of public health emergency when milk or pudding is appropriate); may be administered with food to decrease GI upset; shake suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doryx&reg;: May break up the tablet and sprinkle the delayed release pellets on a spoonful of applesauce. Do",
"     <b>",
"      not",
"     </b>",
"     crush or damage the delayed release pellets; loss or damage of pellets prevents using the dose. Swallow the Doryx&reg;/applesauce mixture immediately without chewing. Discard mixture if it cannot be used immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: For I.V. use only; administer by slow I.V. intermittent infusion over a minimum of 1-2 hours at a concentration not to exceed 1 mg/mL (may be infused over 1-4 hours); concentrations &lt;0.1 mg/mL are not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sclerosing agent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     To control pleural effusions associated with metastatic tumors: Instill into the pleural space through a thoracostomy tube following drainage of the accumulated pleural fluid; clamp the tube then remove the fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For recurrent malignant pleural effusions: Administer via chest tube lavage, clamp tube for 24 hours then drain",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F163370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solutions for I.V. infusion are stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, Ringer's injection, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amiodarone, aztreonam, bivalirudin, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, etoposide phosphate, fenoldopam, filgrastim, fludarabine, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, linezolid, magnesium sulfate, melphalan, meperidine, morphine, ondansetron, oxytocin, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, theophylline, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, heparin, pemetrexed, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Meropenem.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store below 30&deg;C (86&deg;F); protect from light. Reconstituted oral doxycycline suspension is stable for 2 weeks at room temperature; I.V. doxycycline solutions must be protected from direct sunlight",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of infections caused by susceptible",
"     <i>",
"      Rickettsia",
"     </i>",
"     ,",
"     <i>",
"      Chlamydia",
"     </i>",
"     , and",
"     <i>",
"      Mycoplasma",
"     </i>",
"     ; alternative to mefloquine for malaria prophylaxis; treatment for syphilis, uncomplicated",
"     <i>",
"      Neisseria gonorrhoeae",
"     </i>",
"     ,",
"     <i>",
"      Listeria",
"     </i>",
"     ,",
"     <i>",
"      Actinomyces israelii",
"     </i>",
"     ,",
"     <i>",
"      Fusobacterium fusiforme",
"     </i>",
"     , and",
"     <i>",
"      Clostridium",
"     </i>",
"     infections in penicillin-allergic patients; used for community-acquired pneumonia and other common infections due to susceptible organisms; anthrax due to",
"     <i>",
"      Bacillus anthracis",
"     </i>",
"     , including inhalational anthrax (postexposure); treatment of infections caused by uncommon susceptible gram-negative and gram-positive organisms, including",
"     <i>",
"      Borrelia recurrentis",
"     </i>",
"     ,",
"     <i>",
"      Ureaplasma urealyticum",
"     </i>",
"     ,",
"     <i>",
"      Haemophilus ducreyi",
"     </i>",
"     ,",
"     <i>",
"      Yersinia pestis",
"     </i>",
"     ,",
"     <i>",
"      Francisella tularensis",
"     </i>",
"     ,",
"     <i>",
"      Vibrio cholerae",
"     </i>",
"     ,",
"     <i>",
"      Campylobacter fetus",
"     </i>",
"     ,",
"     <i>",
"      Brucella",
"     </i>",
"     spp,",
"     <i>",
"      Bartonella bacilliformis",
"     </i>",
"     , and",
"     <i>",
"      Calymmatobacterium granulomatis",
"     </i>",
"     , Q fever, Lyme disease; treatment of inflammatory lesions associated with rosacea; adjunct to amebicides for intestinal amebiasis; adjunct for treatment of severe acne (FDA approved in ages &ge;8 years and adults); treatment of inflammatory lesions (papules and pustules) associated with rosacea (Oracea&reg;: FDA approved in adults). Has also been used for community-acquired MRSA cellulitis, in ehrlichiosis and management of malignant pleural effusions with intrapleural administration.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxycycline may be confused with dicyclomine, doxepin, doxylamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxy100&trade; may be confused with Doxil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Monodox&reg; may be confused with Maalox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oracea&reg; may be confused with Orencia&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vibramycin&reg; may be confused with vancomycin, Vibativ&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F163369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Intracranial hypertension, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, erythema multiforme, exfoliative dermatitis (rare), photosensitivity, rash, skin hyperpigmentation, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Brown/black discoloration of thyroid gland (no dysfunction reported), hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dysphagia, enterocolitis, esophagitis (rare), esophageal ulcerations (rare), glossitis, inflammatory lesions in anogenital region, nausea, oral (mucosal) pigmentation, pseudomembranous colitis, tooth discoloration (children), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid purpura, anaphylaxis, bulging fontanels (infants), serum sickness, SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse effects as reported in clinical trials occurring greater than placebo:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Periostat&reg;: Diarrhea, dyspepsia, joint pain, menstrual cramp, nausea, dyspepsia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oracea&reg;: Abdominal distention, abdominal pain, anxiety, AST increased, back pain, fungal infection, hyperglycemia, influenza, LDH increased, nasal congestion, nasopharyngitis, pain, sinus headache, sinusitis, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxycycline, tetracycline, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13452559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; increased BUN secondary to antianabolic effects may occur. Hepatotoxicity rarely occurs; if symptomatic, assess liver function tests and discontinue drug. Pseudotumor cerebri has been (rarely) reported with tetracycline use; usually resolves with discontinuation; bulging fontanels have been reported in infants.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Syrup contains sodium metabisulfite which may cause allergic reactions in susceptible individuals. Oracea&reg; should not be used for the treatment or prophylaxis of bacterial infections since the lower dose of drug per capsule may be subtherapeutic and promote resistance.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Photosensitivity reaction may occur with this drug; avoid prolonged exposure to sunlight or tanning equipment. Do not administer to children &lt;8 years of age (except in treatment of anthrax exposure, tickborne rickettsial diseases, or ehrlichiosis); administration of tetracycline 25 mg/kg/day was associated with decreased fibular growth rate in premature infants (reversible with discontinuation of drug); retardation of skeletal development has been observed in fetal animal studies. Use of tetracyclines during tooth development may cause permanent discoloration of the teeth and enamel hypoplasia; staining of teeth is dose-related so that duration of therapy should be minimized; doxycycline may be less likely to stain developing teeth than tetracycline since it binds less strongly to calcium; pseudomembranous colitis has been reported with doxycycline; prolonged use may result in superinfection. Autoimmune  syndromes have been reported. Tetracyclines may induce hyperpigmentation in many organs, including nails, bone, skin (diffuse pigmentation as well as over sites of scars and injury), eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae, and heart valves independently of time or amount of drug administration. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth Subsalicylate: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth subsalicylate. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Tetracycline Derivatives. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Tetracycline Derivatives may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Tetracycline Derivatives. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: Tetracycline Derivatives may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Tetracycline Derivatives. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Tetracycline Derivatives. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tetracycline Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1047106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with iron, calcium, milk, or dairy products may decrease doxycycline absorption; may decrease absorption of calcium, iron, magnesium, zinc, and amino acids",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines cross the placenta and accumulate in developing teeth and long tubular bones. Therapeutic doses of doxycycline during pregnancy are unlikely to produce substantial teratogenic risk, but data are insufficient to say that there is no risk. In general, reports of exposure have been limited to short durations of therapy in the first trimester. Tetracyclines may discolor fetal teeth following maternal use during pregnancy; the specific teeth involved and the portion of the tooth affected depends on the timing and duration of exposure relative to tooth calcification. As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided. Tetracycline medications should be used during pregnancy only when other medications are contraindicated or ineffective (Mylonas, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic monitoring of renal, hematologic, and hepatic function tests; observe for changes in bowel frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits protein synthesis by binding to the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria preventing additions of amino acids to the growing peptide chain; may also cause alterations in the cytoplasmic membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Almost completely from the GI tract; absorption can be reduced by food or milk by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed into body tissues and fluids including synovial and pleural fluid, bile, bronchial secretions; poor penetration into the CSF; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized in the liver; partially inactivated in the GI tract by chelate formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Reduced at high pH; may be clinically significant in patients with gastrectomy, gastric bypass surgery, or who are otherwise deemed achlorhydric",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 12-15 hours (usually increases to 22-24 hours with multiple dosing); Oracea&reg;: 21hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In the urine (23%) and feces (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/10/36005?source=see_link\">",
"      see \"Doxycycline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor teeth if &lt;8 years of age; may discolor fingernails. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection contains ascorbic acid. According to the CDC, staining of the teeth is negligible with short courses of doxycycline and is of minimal consequence in children &gt;6 or 7 years of age because visible tooth formation is complete by this age. Benefits outweigh the risks for rickettsial infections, ehrlichiosis, anthrax, and cholera (CDC, 2006;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009). Oracea&reg; capsules are not bioequivalent to other doxycycline products.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F163308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If a public health emergency is declared and liquid doxycycline is unavailable for the treatment of anthrax, emergency doses may be prepared for children or adults who cannot swallow tablets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Add 20 mL of water to one 100 mg tablet. Allow tablet to soak in the water for 5 minutes to soften. Crush into a fine powder and stir until well mixed. Appropriate dose should be taken from this mixture. To increase palatability, mix with food or drink. If mixing with drink, add 15 mL of  milk, chocolate milk, chocolate pudding, or apple juice to the appropriate dose of mixture. If using apple juice, also add 4 teaspoons of sugar. Doxycycline and water mixture may be stored at room temperature for up to 24 hours.",
"    </p>",
"    <div class=\"reference\">",
"     U.S. Food and Drug Administration, Center for Drug Evaluation and Research, &ldquo;Public Health Emergency Home Preparation Instructions for Doxycycline.&rdquo; Available at",
"     <a href=\"file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130996.htm\" target=\"_blank\">",
"      file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130996.htm",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf%20\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Update: Investigation of Anthrax Associated with Intentional Exposure and Interim Public Health Guidelines, October 2001,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2001, 50(41):889-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/11686472 /pubmed\" id=\"11686472 \" target=\"_blank\">",
"        11686472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman AS, Bakken JS, Folk SM, et al, \"Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis--United States: A Practical Guide for Physicians and Other Health-Care and Public Health Professionals,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-4):1-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/16572105/pubmed\" id=\"16572105\" target=\"_blank\">",
"        16572105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inglesby TV, Henderson DA, Bartlett JG, et al, &ldquo;Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1999, 281(18):1735-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/10328075/pubmed\" id=\"10328075\" target=\"_blank\">",
"        10328075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus Aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"",
"      <i>",
"       Ehrlichia",
"      </i>",
"      and",
"      <i>",
"       Anaplasma",
"      </i>",
"      Infections (Human Ehrlichiosis and Anaplasmosis),\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 284-7. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/3.37.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Tetracyclines,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 739. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/4.1.2",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stern EJ, Uhde KB, Shadomy SV, et al, \"Conference Report on Public Health and Clinical Guidelines for Anthrax,\"",
"      <i>",
"       Emerg Infect Dis",
"      </i>",
"      , 2008, 14(4). Available at",
"      <a href=\"file://wwwnc.cdc.gov/eid/article/14/4/07-0969.htm\" target=\"_blank\">",
"       file://wwwnc.cdc.gov/eid/article/14/4/07-0969.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/18394267/pubmed\" id=\"18394267\" target=\"_blank\">",
"        18394267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Workowski KA, Berman S, and Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12136/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13255 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12136=[""].join("\n");
var outline_f11_54_12136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163331\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163332\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047096\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047087\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163303\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163288\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047100\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163370\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047091\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047099\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163372\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163369\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047103\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452559\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047086\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163358\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163297\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047106\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163300\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163313\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047095\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047085\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047102\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047093\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047104\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163308\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=related_link\">",
"      Doxycycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/10/36005?source=related_link\">",
"      Doxycycline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_54_12137="Recombinant human growth hormone (somatropin): Drug information";
var content_f11_54_12137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Recombinant human growth hormone (somatropin): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/39/20085?source=see_link\">",
"    see \"Recombinant human growth hormone (somatropin): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"    see \"Recombinant human growth hormone (somatropin): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Genotropin Miniquick&reg;;",
"     </li>",
"     <li>",
"      Genotropin&reg;;",
"     </li>",
"     <li>",
"      Humatrope&reg;;",
"     </li>",
"     <li>",
"      Norditropin FlexPro&reg;;",
"     </li>",
"     <li>",
"      Norditropin&reg; NordiFlex&reg;;",
"     </li>",
"     <li>",
"      Nutropin AQ Pen&reg;;",
"     </li>",
"     <li>",
"      Nutropin AQ&reg;;",
"     </li>",
"     <li>",
"      Nutropin AQ&reg; NuSpin&trade;;",
"     </li>",
"     <li>",
"      Nutropin&reg;;",
"     </li>",
"     <li>",
"      Omnitrope&reg;;",
"     </li>",
"     <li>",
"      Saizen&reg;;",
"     </li>",
"     <li>",
"      Serostim&reg;;",
"     </li>",
"     <li>",
"      Tev-Tropin&reg;;",
"     </li>",
"     <li>",
"      Zorbtive&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humatrope&reg;;",
"     </li>",
"     <li>",
"      Norditropin Simplexx;",
"     </li>",
"     <li>",
"      Nutropin AQ Pen&reg;;",
"     </li>",
"     <li>",
"      Nutropin AQ&reg; NuSpin&trade;;",
"     </li>",
"     <li>",
"      Nutropin&reg;;",
"     </li>",
"     <li>",
"      Nutropin&reg; AQ;",
"     </li>",
"     <li>",
"      Omnitrope&reg;;",
"     </li>",
"     <li>",
"      Saizen&reg;;",
"     </li>",
"     <li>",
"      Serostim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F222378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Growth Hormone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F222360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Growth hormone deficiency:",
"     </b>",
"     Adjust dose based on individual requirements: To minimize adverse events in older or overweight patients, reduced dosages may be necessary. During therapy, dosage should be decreased if required by the occurrence of side effects or excessive IGF-I levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Weight-based dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Norditropin&reg;:",
"     </i>",
"     SubQ: Initial dose &le;0.004 mg/kg/day; after 6 weeks of therapy, may increase dose up to 0.016 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nutropin&reg;, Nutropin&reg; AQ:",
"     </i>",
"     SubQ: &le;0.006 mg/kg/day; dose may be increased up to a maximum of 0.025 mg/kg/day in patients &lt;35 years of age, or up to a maximum of 0.0125 mg/kg/day in patients &ge;35 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Humatrope&reg;:",
"     </i>",
"     SubQ: &le;0.006 mg/kg/day; dose may be increased up to a maximum of 0.0125 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Genotropin&reg;, Omnitrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: &le;0.04 mg/kg divided into equal doses 6-7 days per week; dose may be increased at 4- to 8-week intervals to a maximum of 0.08 mg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Saizen&reg;:",
"     </i>",
"     SubQ: &le;0.005 mg/kg/day; dose may be increased to not more than 0.01 mg/kg/day after 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Nonweight-based dosing:",
"      </i>",
"     </b>",
"     SubQ: Initial: 0.2 mg/day (range: 0.15-0.3 mg/day); may increase every 1-2 months by 0.1-0.2 mg/day based on response and/or serum IGF-I levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment with estrogen supplementation (growth hormone deficiency):",
"     </i>",
"     Larger doses of somatropin may be needed for women taking oral estrogen replacement products; dosing not affected by topical products",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV-associated adipose redistribution syndrome (HARS) (unlabeled use):",
"     </b>",
"     Serostim&reg;: SubQ: Induction: 4 mg once daily at bedtime for 12 weeks; Maintenance: 2 mg or 4 mg every other day at bedtime for 12-24 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Every-other-day dosing during induction has also been studied. Although a greater response was seen with daily dosing, it was associated with an increased incidence of adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      HIV patients with wasting or cachexia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Serostim&reg;:",
"     </i>",
"     SubQ: 0.1 mg/kg once daily at bedtime (maximum: 6 mg/day). Alternately, patients at risk for side effects may be started at 0.1 mg/kg every other day. Patients who continue to lose weight after 12 weeks should be re-evaluated for opportunistic infections or other clinical events; rotate injection sites to avoid lipodystrophy. Adjust dose if needed to manage side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Daily dose based on body weight:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;35 kg: 0.1 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     35-45 kg: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     45-55 kg: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;55 kg: 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Short-bowel syndrome:",
"     </b>",
"     <i>",
"      Zorbtive&reg;:",
"     </i>",
"     SubQ: 0.1 mg/kg once daily for 4 weeks (maximum: 8 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fluid retention (moderate) or arthralgias:",
"     </i>",
"     Treat symptomatically or reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe toxicity:",
"     </i>",
"     Discontinue therapy for up to 5 days; when symptoms resolve, restart at 50% of dose. If severe toxicity recurs or does not disappear within 5 days after discontinuation, permanently discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F222371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"      see \"Recombinant human growth hormone (somatropin): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Growth hormone deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Genotropin&reg;, Omnitrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.16-0.24 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Humatrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.18-0.3 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Norditropin&reg;:",
"     </i>",
"     SubQ: 0.024-0.034 mg/kg/day, 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Nutropin&reg;, Nutropin&reg; AQ:",
"     </i>",
"     SubQ: Weekly dosage: 0.3 mg/kg divided into equal daily doses; pubertal patients: &le;0.7 mg/kg divided into equal daily doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Tev-Tropin&reg;: SubQ:",
"     </i>",
"     Up to 0.1 mg/kg/dose administered 3 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Saizen&reg;:",
"     </i>",
"     I.M., SubQ: Weekly dosage: 0.18 mg/kg divided into equal daily doses",
"     <b>",
"      or",
"     </b>",
"     as 0.06 mg/kg/dose administered 3 days per week",
"     <b>",
"      or",
"     </b>",
"     as 0.03 mg/kg/dose administered 6 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued when patient has reached satisfactory adult height, when epiphyses have fused, or when the patient ceases to respond. Growth of 5 cm/year or more is expected, if growth rate does not exceed 2.5 cm in a 6-month period, double the dose for the next 6 months; if there is still no satisfactory response, discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic renal insufficiency (CRI):",
"     </b>",
"     <i>",
"      Nutropin&reg;, Nutropin&reg; AQ:",
"     </i>",
"     SubQ: Weekly dosage: 0.35 mg/kg divided into daily injections; continue until the time of renal transplantation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosage recommendations in patients treated for CRI who require dialysis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Hemodialysis:",
"     </i>",
"     Administer dose at night prior to bedtime or at least 3-4 hours after hemodialysis to prevent hematoma formation from heparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      CCPD:",
"     </i>",
"     Administer dose in the morning following dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      CAPD:",
"     </i>",
"     Administer dose in the evening at the time of overnight exchange",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Turner syndrome:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Genotropin&reg;, Omnitrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.33 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Humatrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.375 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Norditropin&reg;:",
"     </i>",
"     SubQ: Up to 0.067 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Nutropin&reg;, Nutropin&reg; AQ:",
"     </i>",
"     SubQ: Weekly dosage: &le;0.375 mg/kg divided into equal doses 3-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prader-Willi syndrome:",
"     </b>",
"     <i>",
"      Genotropin&reg;, Omnitrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.24 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small for gestational age:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Genotropin&reg;, Omnitrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.48 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Humatrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.47 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Norditropin&reg;:",
"     </i>",
"     SubQ: Up to 0.067 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate dosing (small for gestational age):",
"     </i>",
"     In older/early pubertal children or children with very short stature, consider initiating therapy at higher doses (0.067 mg/kg/day) and then consider reducing the dose (0.033 mg/kg/day) if substantial catch-up growth observed. In younger children (&lt;4 years) with less severe short stature, consider initiating therapy with lower doses (0.033 mg/kg/day) and then titrating the dose upwards as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Idiopathic short stature:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Genotropin&reg;, Omnitrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.47 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Humatrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.37 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nutropin&reg;, Nutropin AQ&reg;:",
"     </i>",
"     SubQ: Weekly dosage: Up to 0.3 mg/kg divided into equal daily doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      SHOX deficiency:",
"     </b>",
"     <i>",
"      Humatrope&reg;:",
"     </i>",
"     SubQ: Weekly dosage: 0.35 mg/kg divided into equal doses 6-7 days per week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV patients with wasting or cachexia (unlabeled use):",
"     </b>",
"     <i>",
"      Serostim&reg;:",
"     </i>",
"     SubQ: Limited data; doses of 0.04 mg/kg/day were reported in five children, 6-17 years of age; doses of 0.07 mg/kg/day were reported in six children, 8-14 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Noonan syndrome:",
"     </b>",
"     <i>",
"      Norditropin&reg;:",
"     </i>",
"     SubQ: Up to 0.066 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F222361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients &ge;65 years of age may be more sensitive to the action of growth hormone and more prone to adverse effects; in general, dosing should be cautious, beginning at low end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F222362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reports indicate patients with chronic renal failure tend to have decreased clearance; specific dosing suggestions not available",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F222363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clearance may be reduced in patients with severe hepatic dysfunction; specific dosing suggestions are not available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [rDNA origin]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genotropin&reg;: 5 mg, 12 mg [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humatrope&reg;: 5 mg [DSC], 6 mg, 12 mg, 24 mg [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutropin&reg;: 5 mg, 10 mg [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnitrope&reg;: 5.8 mg [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saizen&reg;: 5 mg [contains benzyl alcohol (in diluent), sucrose 34.2 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saizen&reg;: 8.8 mg [contains benzyl alcohol (in diluent), sucrose 60.2 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Saizen&reg;: 8.8 mg [contains sucrose 60.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serostim&reg;: 4 mg [contains benzyl alcohol (in diluent), sucrose 27.3 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serostim&reg;: 5 mg [contains sucrose 34.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serostim&reg;: 6 mg [contains sucrose 41 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tev-Tropin&reg;: 5 mg [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zorbtive&reg;: 8.8 mg [contains benzyl alcohol (in diluent), sucrose 60.19 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [rDNA origin, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genotropin Miniquick&reg;: 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, 2 mg [delivers 0.25 mL; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [rDNA origin]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norditropin FlexPro&reg;: 5 mg/1.5 mL (1.5 mL); 10 mg/1.5 mL (1.5 mL); 15 mg/1.5 mL (1.5 mL) [prefilled pen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norditropin&reg; NordiFlex&reg;: 30 mg/3 mL (3 mL) [prefilled pen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutropin AQ Pen&reg;: 10 mg/2 mL (2 mL); 20 mg/2 mL (2 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutropin AQ&reg;: 10 mg/2 mL (2 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutropin AQ&reg; NuSpin&trade;: 5 mg/2 mL (2 mL); 10 mg/2 mL (2 mL); 20 mg/2 mL (2 mL) [prefilled pen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnitrope&reg;: 5 mg/1.5 mL (1.5 mL) [contains benzyl alcohol; cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnitrope&reg;: 10 mg/1.5 mL (1.5 mL) [cartridge]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F222340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not shake; administer SubQ or I.M. (not all products are approved for I.M. administration). Rotate administration sites to avoid tissue atrophy. When administering to newborns, do not reconstitute with a diluent that contains benzyl alcohol; sterile water for injection may be used as an alternative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norditropin&reg; cartridge must be administered using the corresponding color-coded NordiPen&reg; injection pen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omnitrope&reg;: Solution in the cartridges must be administered using the Omnitrope&reg; pen; when installing a new cartridge, prime pen prior to first use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Humatrope&reg;: When administering for growth hormone deficiency, SubQ route is preferred",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tev-Tropin&reg;: SubQ injections of solutions &gt;1 mL not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F222339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of growth failure due to inadequate endogenous growth hormone secretion (Genotropin&reg;, Humatrope&reg;, Norditropin&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;, Saizen&reg;, Tev-Tropin&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of short stature associated with Turner syndrome (Genotropin&reg;, Humatrope&reg;, Norditropin&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of Prader-Willi syndrome (Genotropin&reg;, Omnitrope&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of growth failure associated with chronic renal insufficiency (CRI) up until the time of renal transplantation (Nutropin&reg;, Nutropin AQ&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by 2 years of age (Genotropin&reg;, Omnitrope&reg;) or by 2-4 years of age (Humatrope&reg;, Norditropin&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of idiopathic short stature (nongrowth hormone-deficient short stature) defined by height standard deviation score (SDS) &le;-2.25 and growth rate not likely to attain normal adult height (Genotropin&reg;, Humatrope&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of short stature or growth failure associated with short stature homeobox gene (SHOX) deficiency (Humatrope&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of short stature associated with Noonan syndrome (Norditropin&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HIV patients with wasting or cachexia with concomitant antiviral therapy (Serostim&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Replacement of endogenous growth hormone in patients with adult growth hormone deficiency who meet both of the following criteria (Genotropin&reg;, Humatrope&reg;, Norditropin&reg;, Nutropin&reg;, Nutropin AQ&reg;, Omnitrope&reg;, Saizen&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Biochemical diagnosis of adult growth hormone deficiency by means of a subnormal response to a standard growth hormone stimulation test (peak growth hormone &le;5 mcg/L). Confirmatory testing may not be required in patients with congenital/genetic growth hormone deficiency or multiple pituitary hormone deficiencies due to organic diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      and",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult-onset: Patients who have adult growth hormone deficiency whether alone or with multiple hormone deficiencies (hypopituitarism) as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Childhood-onset: Patients who were growth hormone deficient during childhood, confirmed as an adult before replacement therapy is initiated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of short-bowel syndrome (Zorbtive&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F222374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric HIV patients with wasting/cachexia (Serostim&reg;); HIV-associated adipose redistribution syndrome (HARS) (Serostim&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F222386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Humatrope&reg; may be confused with homatropine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Somatrem may be confused with somatropin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Somatropin may be confused with homatropine, sumatriptan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F222376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Growth hormone deficiency:",
"     </b>",
"     Adverse reactions reported with growth hormone deficiency vary greatly by age. Generally, percentages are less in pediatric patients than adults, and many of the reactions reported in adults are dose related. Percentages reported also vary by product. Below is a listing by age group; events reported more commonly overall are noted with an asterisk (*).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Antibodies development, arthralgia, benign intracranial hypertension, edema, eosinophilia, glycosuria, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     increased, headache, hematoma, hematuria, hyperglycemia (mild), hypertriglyceridemia, hypoglycemia, hypothyroidism, injection site reaction, intracranial tumor, leg pain, lipoatrophy, leukemia, meningioma, muscle pain, papilledema, pseudotumor cerebri, psoriasis exacerbation, rash, scoliosis progression, seizure, slipped capital femoral epiphysis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Acne, ALT increased, AST increased, arthralgia*, back pain, bronchitis, carpal tunnel syndrome, chest pain, cough, depression, diabetes mellitus (type 2), diaphoresis, dizziness, edema*, fatigue, flu-like syndrome*, gastritis, glucose intolerance, glucosuria, headache*, hyperglycemia (mild), hypertension, hypoesthesia, hypothyroidism, infection, insomnia, insulin resistance, joint disorder, leg edema, muscle pain, myalgia*, nausea, pain in extremities, paresthesia*, peripheral edema*, pharyngitis, retinopathy, rhinitis, skeletal pain*, stiffness in extremities, surgical procedure, upper respiratory tract infection, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Additional/postmarketing reactions observed with growth hormone deficiency: Gynecomastia, increased growth of pre-existing nevi, pancreatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      HARS:",
"     </b>",
"     Serostim&reg;: Limited to &gt;10%: Edema (peripheral) (19% to 45%), arthralgia (28% to 37%), pain (extremity) (5% to 19%), hypoesthesia (9% to 15%), headache (4% to 14%), blood glucose increased (4% to 14%), paresthesia (11% to 13%), myalgia (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Idiopathic short stature:",
"     </b>",
"     Percentages reported using Humatrope&reg; versus placebo: Myalgia (24%), scoliosis (19%), otitis media (16%), arthralgia (11%), arthrosis (11%), hyperlipidemia (8%), gynecomastia (5%), hip pain (3%), hypertension (3%). Additional adverse reactions listed as reported using other products from ISS NCGS Cohort (frequencies &lt;1%): Aggressiveness, benign intracranial hypertension, diabetes, edema, hair loss, headache, injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prader-Willi syndrome:",
"     </b>",
"     Genotropin&reg; (frequency not defined): Aggressiveness, arthralgia, edema, hair loss, headache, benign intracranial hypertension, myalgia; fatalities associated with use in this population have been reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Turner syndrome:",
"     </b>",
"     Percentages reported using Humatrope&reg; compared to untreated patients. Additional adverse reactions reported from other products, frequency not specified: Surgical procedures (45%), otitis media (43%), ear disorders (18%), joint pain, respiratory illness, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV patients with wasting or cachexia:",
"     </b>",
"     Serostim&reg; (limited to &ge;5%): Musculoskeletal disorders (arthralgia, arthrosis, myalgia: 78%), peripheral edema (26%), headache (13%), nausea (9%), paresthesia (8%), edema (6%), gynecomastia (6%), hypoesthesia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Short-bowel syndrome:",
"     </b>",
"     Zorbtive&reg; (limited to &gt;10%): Peripheral edema (69% to 81%), facial edema (44% to 50%), arthralgia (31% to 44%), nausea (13% to 31%), injection site pain (up to 31%), flatulence (25%), injection site reaction (19% to 25%), abdominal pain (13% to 25%), vomiting (19%), pain (6% to 19%), chest pain (up to 19%), dehydration (up to 19%), infection (up to 19%), rhinitis (up to 19%), hearing symptoms (13%), dizziness (6% to 13%), rash (6% to 13%), diaphoresis (up to 13%), generalized edema (up to 13%), malaise (up to 13%), moniliasis (up to 13%), myalgia (up to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      SHOX deficiency:",
"     </b>",
"     Humatrope&reg;: Arthralgia (11%), gynecomastia (8%), excessive cutaneous nevi (7%), scoliosis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small for gestational age:",
"     </b>",
"     Genotropin&reg;, Humatrope&reg; (frequency not defined): Mild, transient hyperglycemia; benign intracranial hypertension (rare); central precocious puberty; jaw prominence (rare); aggravation of pre-existing scoliosis (rare); injection site reactions; progression of pigmented nevi; carpal tunnel syndrome (rare) diabetes mellitus (rare); otitis media; headache; slipped capital femoral epiphysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F222343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to growth hormone or any component of the formulation; growth promotion in pediatric patients with closed epiphyses; progression or recurrence of any underlying intracranial lesion or actively growing intracranial tumor; acute critical illness due to complications following open heart or abdominal surgery; multiple accidental trauma or acute respiratory failure; evidence of active malignancy; active proliferative or severe nonproliferative diabetic retinopathy; use in patients with Prader-Willi syndrome",
"     <b>",
"      without",
"     </b>",
"     growth hormone deficiency (except Genotropin&reg;) or in patients with Prader-Willi syndrome",
"     <b>",
"      with",
"     </b>",
"     growth hormone deficiency who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F222327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention: May occur frequently in adults during use; manifestations of fluid retention (eg, edema, arthralgia, myalgia, nerve compression syndromes/paresthesias) are generally transient and dose dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Reactions are possible; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intracranial hypertension (IH): IH with headache, nausea, papilledema, visual changes, and/or vomiting has been reported with somatropin; funduscopic examination prior to initiation of therapy and periodically thereafter is recommended. Treatment should be discontinued in patients who develop papilledema; resuming treatment at a lower dose may be considered once IH-associated signs and symptoms have resolved. Patients with Turner syndrome, chronic renal failure and Prader-Willi syndrome may be at increased risk for IH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neoplasm: Use in contraindicated with active malignancy. Monitor patients with pre-existing tumors or growth failure secondary to an intracranial lesion for recurrence or progression of underlying disease; discontinue therapy with evidence of recurrence. An increased risk of second neoplasm has been reported in childhood cancer survivors treated with somatropin; the most common second neoplasms were meningiomas in patients treated with radiation to the head for their first neoplasm. Monitor patients for any malignant transformation of skin lesions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Has been rarely reported; incidence in children (especially girls) with Turner syndrome may be greater than adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Slipped capital epiphyses: Patients with growth hormone deficiency may develop slipped capital epiphyses more frequently; evaluate any child with new onset of a limp or with complaints of hip or knee pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute critical illness: Initiation of somatropin is contraindicated with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure; mortality may be increased. The safety of continuing somatropin in patients who develop these illnesses during therapy has not been established; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Childhood-onset adult growth hormone deficiency (GHD): Children with epiphyseal closure who are treated with somatropin replacement therapy should be reassessed before continuation of therapy at reduced dose recommended for GH deficient adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus (DM): Use with caution in patients with diabetes or with risk factors for impaired glucose tolerance; may decrease insulin sensitivity. Risk factors for diabetes in this population include obesity, Turner syndrome, or a family history of DM. Adjustment of antidiabetic medications may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoadrenalism: Patients with hypoadrenalism may require increased dosages of glucocorticoids (especially cortisone acetate and prednisone) due to somatropin-mediated inhibition of 11 beta-hydroxysteroid dehydrogenase type 1; undiagnosed central hypoadrenalism may be unmasked. Excessive glucocorticoid therapy may inhibit the growth promoting effects of somatropin in children; monitor and adjust glucocorticoids carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypopituitarism: Closely monitor other hormonal replacement treatments in patients with hypopituitarism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: Untreated/undiagnosed hypothyroidism may decrease response to therapy; monitor thyroid function test periodically and initiate/adjust thyroid replacement therapy as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Noonan syndrome: Safety and efficacy have not been established for the treatment of Noonan syndrome in children with significant cardiac disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Increased incidence of adverse events may occur when using a weight-based dosing regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prader-Willi syndrome: Fatalities have been reported in pediatric patients with Prader-Willi syndrome following the use of growth hormone. The reported fatalities occurred in patients with one or more risk factors, including severe obesity, sleep apnea, respiratory impairment, or unidentified respiratory infection; male patients with one or more of these factors may be at greater risk. Treatment interruption is recommended in patients who show signs of upper airway obstruction, including the onset of, or increased, snoring. In addition, evaluation of and/or monitoring for sleep apnea and respiratory infections are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Scoliosis: Progression of scoliosis may occur in children experiencing rapid growth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Turner syndrome: Patients with Turner syndrome are at increased risk for otitis media and other ear/hearing disorders, cardiovascular disorders (including stroke, aortic aneurysm, hypertension), and thyroid disease, monitor carefully",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid in this patient population except as hormone replacement following pituitary gland removal; use results in minimal effect on body composition and is associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, and impaired fasting glucose (Beers Criteria). Elderly may be more sensitive to the actions of somatropin; consider lower starting doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV patients: Patients with HIV infection should be maintained on antiretroviral therapy to prevent the potential increase in viral replication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Products may contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates; when administering to newborns, reconstitute with sterile water or saline for injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; M-cresol: Some products may contain m-cresol as a preservative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Not for I.V. injection. Subcutaneous administration sites must be rotated to prevent tissue atrophy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F222332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Somatropin may diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cortisone: Somatropin may diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women. Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ethinyl Estradiol; Mestranol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Somatropin may diminish the therapeutic effect of PredniSONE. Growth hormone may reduce the conversion of prednisone to the active prednisolone metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (depending upon manufacturer) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3984740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Reproduction studies have not been conducted with all agents. During normal pregnancy, maternal production of endogenous growth hormone decreases as placental growth hormone production increases. Data with somatropin use during pregnancy is limited.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F222366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F222346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prader-Willi syndrome: All patients should have effective weight control (use is contraindicated in severely-obese patients).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Short-bowel syndrome: Intravenous parenteral nutrition requirements may need reassessment as gastrointestinal absorption improves.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F222345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Norditropin FlexPro Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/1.5 mL (1.5 mL): $485.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/1.5 mL (1.5 mL): $970.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/1.5 mL (1.5 mL): $1456.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Norditropin NordiFlex Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/3 mL (3 mL): $2912.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nutropin AQ NuSpin 10 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/2 mL (2 mL): $980.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nutropin AQ NuSpin 20 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $1961.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nutropin AQ NuSpin 5 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/2 mL (2 mL): $490.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nutropin AQ Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/2 mL (2 mL): $980.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $1961.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nutropin AQ Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/2 mL (2 mL): $980.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Omnitrope Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/1.5 mL (1.5 mL): $436.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/1.5 mL (1.5 mL): $873.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Genotropin MiniQuick Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg (1): $20.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg (1): $41.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg (1): $62.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 mg (1): $83.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $104.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2 mg (1): $125.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.4 mg (1): $146.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.6 mg (1): $167.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.8 mg (1): $188.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (1): $208.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Genotropin Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $479.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (1): $1150.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Humatrope Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $489.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (1): $586.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (1): $1173.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24 mg (1): $2347.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Nutropin Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $988.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Omnitrope Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.8 mg (1): $316.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Saizen Click.Easy Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.8 mg (1): $768.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Saizen Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $480.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.8 mg (1): $768.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Serostim Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (1): $260.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $324.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (1): $388.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Tev-Tropin Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $307.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Zorbtive Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.8 mg (1): $998.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F222336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth curve, Tanner staging (children), periodic thyroid function tests, bone age (annually), periodical urine testing for glucose, somatomedin C (IGF-I) levels; funduscopic examinations at initiation of therapy and periodically during treatment; serum phosphorus, alkaline phosphatase and parathyroid hormone. If growth deceleration is observed in children treated for growth hormone deficiency, and not due to other causes, evaluate for presence of antibody formation. Periodic blood glucose monitoring; strict blood glucose monitoring in patients with diabetes. Progression or recurrence of pre-existing tumors or malignant transformation of skin lesions.",
"     <b>",
"      Note:",
"     </b>",
"     Practice guidelines recommend monitoring for efficacy and adverse effects every 1-2 months during dose titration and semiannually, thereafter (TES, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CRI: Progression of renal osteodystrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prader-Willi syndrome: Monitor for sleep apnea, respiratory infections, snoring (onset of or increased)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Turner syndrome: Ear disorders including otitis media; cardiovascular disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Noonan syndrome: Prior to use, verify short stature syndrome.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F222347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Declage (KP);",
"     </li>",
"     <li>",
"      Genheal (PH, TH);",
"     </li>",
"     <li>",
"      Genotonorm (FR);",
"     </li>",
"     <li>",
"      Genotonorm Miniquick (FR);",
"     </li>",
"     <li>",
"      Genotropin (AE, AU, BG, BH, CH, CL, CR, CY, DE, DO, EG, GR, GT, HK, HN, ID, IL, IN, IQ, IR, IT, JO, KW, LB, LY, NI, NL, NZ, OM, PA, PK, PL, QA, RU, SA, SV, SY, TH, TR, UY, VE, YE);",
"     </li>",
"     <li>",
"      Growject BC (JP);",
"     </li>",
"     <li>",
"      Growtropin-Aq (CO);",
"     </li>",
"     <li>",
"      HHT (EC);",
"     </li>",
"     <li>",
"      Humatrope (AR, BF, BJ, BR, CI, CN, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, PE, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Maxomat (FR);",
"     </li>",
"     <li>",
"      Nordilet (KP);",
"     </li>",
"     <li>",
"      Norditropin (AR, BR, CL, JP, KP);",
"     </li>",
"     <li>",
"      Norditropin Nordilet (SG, TH);",
"     </li>",
"     <li>",
"      Norditropin S (JP);",
"     </li>",
"     <li>",
"      Norditropin Simplex (KP);",
"     </li>",
"     <li>",
"      Norditropin Simplexx (DE, ES, NZ);",
"     </li>",
"     <li>",
"      Novell-Eutropin (ID);",
"     </li>",
"     <li>",
"      Nutropin AQ (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Nutropinaq (FR);",
"     </li>",
"     <li>",
"      Omnitrope (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Saizen (AR, AU, BR, CH, CL, CR, DE, DO, EC, FR, GT, HK, HN, ID, IL, MX, MY, NI, NZ, PA, PE, PH, SV, TW);",
"     </li>",
"     <li>",
"      Scitropin (AU, PH);",
"     </li>",
"     <li>",
"      Scitropina (SG);",
"     </li>",
"     <li>",
"      Serostim (MX);",
"     </li>",
"     <li>",
"      Somatonorm (HR);",
"     </li>",
"     <li>",
"      Valtropin (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Zomacton (AU, HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F222326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Somatropin is a purified polypeptide hormones of recombinant DNA origin; somatropin contains the identical sequence of amino acids found in human growth hormone; human growth hormone assists growth of linear bone, skeletal muscle, and organs by stimulating chondrocyte proliferation and differentiation, lipolysis, protein synthesis, and hepatic glucose output; stimulates erythropoietin which increases red blood cell mass; exerts both insulin-like and diabetogenic effects; enhances the transmucosal transport of water, electrolytes, and nutrients across the gut",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F222342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Duration: Maintains supraphysiologic levels for 18-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M., SubQ: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and renal (~90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: ~70% to 90%;",
"     <b>",
"      Note:",
"     </b>",
"     Variable; product-dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Preparation and route of administration dependent; SubQ: ~2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (small amount)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Association of Clinical Endocrinologists (AACE) Growth Hormone Task Force, &ldquo;AACE Medical Guidelines for Clinical Practice for Growth Hormone Use in Adults and Children -- 2003 Update,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2003, 9(1):64-76.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blum WF, Crowe BJ, Quigley CA, et al, &ldquo;Growth Hormone is Effective in Treatment of Short Stature Associated With SHOX Deficiency: Two-year Results of a Randomized, Controlled, Multi-Center Trial,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2007, 92(1):219-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/17047016/pubmed\" id=\"17047016\" target=\"_blank\">",
"        17047016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clayton PE, Cianfarani S, Czernichow P, et al, &ldquo;Consensus Statement: Management of the Child Born Small for Gestational Age Through to Adulthood: A Consensus Statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society,&rdquo;",
"      <i>",
"       J Clin Endrocrinol Metab",
"      </i>",
"      , 2007, 92(3):804-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/17200164/pubmed\" id=\"17200164\" target=\"_blank\">",
"        17200164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen P, Rogol AD, Deal CL, et al, &ldquo;Consensus Statement on the Diagnosis and Treatment of Children With Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93(11):4210-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/18782877/pubmed\" id=\"18782877\" target=\"_blank\">",
"        18782877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook DM, Ludlam WH, and Cook MB. &ldquo;Route of Estrogen Administration Helps to Determine Growth Hormone (GH) Replacement Dose in GH-Deficient Adults,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1999, 84(11):3956-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/10566634/pubmed\" id=\"10566634\" target=\"_blank\">",
"        10566634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Evaluation and Treatment of Adult Growth-Hormone Deficiency: An Endocrine Society Clinical Practice Guideline,&rdquo; The Endocrine Society (TES).   Available at file://www.endo-society.org/guidelines/final/upload/042506_CG_HormoneBook.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuglsang J, Lauszus F, Orskov H, et al, &ldquo;Placental Growth Hormone During Pregnancy in a Growth Hormone Deficient Woman With Type 1 Diabetes Compared to a Matching Diabetic Control Group,&rdquo;",
"      <i>",
"       Growth Horm IGF Res",
"      </i>",
"      , 2004, 14(1):66-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/14700557/pubmed\" id=\"14700557\" target=\"_blank\">",
"        14700557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      GH Research Society, &ldquo;Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2000, 85(11):3990-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/11095419/pubmed\" id=\"11095419\" target=\"_blank\">",
"        11095419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grunfeld C, Thompson M, Brown SJ, et al, &ldquo;Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12-Week Induction and 24-Week Maintenance Therapy. Study 24380 Investigators Group,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 2007, 45(3):286-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/17592343/pubmed\" id=\"17592343\" target=\"_blank\">",
"        17592343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howrie DL, &ldquo;Growth Hormone for the Treatment of Growth Failure in Children,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1987, 6(4):283-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/3311576/pubmed\" id=\"3311576\" target=\"_blank\">",
"        3311576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kotler DP, Muurahainen N, Grunfeld C, et al, &ldquo;Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients. Serostim in Adipose Redistribution Syndrome Study Group,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Synd",
"      </i>",
"      , 2004, 35(3):239-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/15076238/pubmed\" id=\"15076238\" target=\"_blank\">",
"        15076238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molitch ME, Clemmons DR, Malozowski S, et al, &ldquo;Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2006, 91(5):1621-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/54/12137/abstract-text/16636129/pubmed\" id=\"16636129\" target=\"_blank\">",
"        16636129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9456 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12137=[""].join("\n");
var outline_f11_54_12137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222357\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222358\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222378\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222360\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222371\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222361\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222362\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222363\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222338\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222323\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222340\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222339\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222374\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222386\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222376\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222343\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222327\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300073\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222332\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222334\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3984740\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222366\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222346\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222345\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222336\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222347\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222326\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222342\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9456|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/39/20085?source=related_link\">",
"      Recombinant human growth hormone (somatropin): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=related_link\">",
"      Recombinant human growth hormone (somatropin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_54_12138="Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)";
var content_f11_54_12138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/54/12138/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/54/12138/contributors\">",
"     Uta Erdbruegger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/54/12138/contributors\">",
"     Mark D Okusa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/54/12138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/54/12138/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/54/12138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/54/12138/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/54/12138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI), previously called acute renal failure, is a common clinical problem [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The 2012 KDIGO Clinical Practice Guidelines for Acute Kidney Injury defined AKI as",
"    <strong>",
"     one or more of three criteria",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/1\">",
"     1",
"    </a>",
"    ]. The first two were a rise in serum creatinine of at least 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (26.5",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    over a 48 hour period",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &ge;1.5 times the baseline value within the seven previous days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The third criterion was a urine volume less &le;0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for six hours. However, in a 70 kg adult male, this would represent a urine volume as high as 210",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    in six hours which, if maintained, would be 840",
"    <span class=\"nowrap\">",
"     mL/day.",
"    </span>",
"    Many healthy individuals could meet this criterion if they had limited fluid intake. Thus, the authors and reviewers of this topic do",
"    <strong>",
"     not",
"    </strong>",
"    agree with making a diagnosis of AKI based solely upon the urine volume.",
"   </p>",
"   <p>",
"    Other definitions and severity staging of AKI have also been proposed. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two major causes of AKI that occur in the hospital are prerenal disease and acute tubular necrosis (ATN). Together, they account for approximately 65 to 75 percent of cases of AKI. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Frequency of prerenal disease and ATN as a cause of acute kidney injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology, etiology, clinical presentation, and evaluation and diagnosis of prerenal disease and ATN as a cause of AKI. The diagnostic approach to patients with acute or chronic kidney disease, the possible prevention and management of ATN, and renal and patient outcomes after ATN are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKI is characterized by an abrupt decrease in renal function. The etiology can be classified into prerenal, intrinsic renal, and postrenal causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\", section on 'Major causes of kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9870312\">",
"    <span class=\"h2\">",
"     Prerenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased kidney function due to prerenal disease occurs in two settings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/8\">",
"     8",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H914954238\">",
"     'Causes of prerenal disease'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When renal ischemia is part of a generalized decrease in tissue perfusion",
"     </li>",
"     <li>",
"      When there is selective renal ischemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic hypoperfusion is initially sensed by cardiac and arterial receptors that respond to changes in pressure (or stretch). When the mean arterial pressure is reduced, due to a reduction in either in cardiac output or systemic vascular resistance, activation of these receptors increases sympathetic neural tone and the release of both renin (leading to the generation of angiotensin II) and antidiuretic hormone. The ensuing arteriolar and venular constriction and stimulation of cardiac function return the systemic blood pressure and cardiac output toward normal. The arteriolar vasoconstriction occurs primarily in the renal, splanchnic, and musculocutaneous circulations, resulting in the relative preservation of blood flow to the heart and brain.",
"   </p>",
"   <p>",
"    Although these are appropriate systemic responses, renal vasoconstriction can diminish renal blood flow and the glomerular filtration rate (GFR), which is flow-dependent. In addition, if the compensatory systemic responses are incomplete, persistent reductions in cardiac output",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arterial pressure can contribute to the decline in GFR.",
"   </p>",
"   <p>",
"    A common cause of prerenal disease is true volume depletion, which includes hypovolemia caused by dehydration, hemorrhage, or renal (diuretics) or gastrointestinal (vomiting, diarrhea) fluid loss. Renal perfusion can also be reduced in edematous states such as heart failure and cirrhosis due to myocardial dysfunction and splanchnic venous pooling and systemic vasodilation, respectively. (See",
"    <a class=\"local\" href=\"#H914954238\">",
"     'Causes of prerenal disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With all of these processes that cause prerenal disease, the GFR is diminished because of decreased renal blood flow. The glomeruli, kidney tubules, and interstitium are intact. The appropriate treatment is to increase renal perfusion, as with volume repletion in patients with true volume depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link&amp;anchor=H8#H8\">",
"     \"Maintenance and replacement fluid therapy in adults\", section on 'Replacement fluid therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9870320\">",
"    <span class=\"h2\">",
"     Acute tubular necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe ischemia, ATN can occur. This can result in histologic changes, including necrosis with denuding of the epithelium and occlusion of the tubular lumen by casts and cell debris. Postischemic (also called ischemic) ATN is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this injury pattern is not universal and the pathophysiologic mechanisms may be different in certain disease conditions. As an example, sepsis-associated high cardiac output failure is associated with dilatation of both afferent and efferent arterioles, which will reduce renovascular resistance and tend to maintain renal blood flow. However, the efferent arterioles usually dilate to a greater degree, which can lead to a decrease in intraglomerular pressure and therefore in GFR. Most of the evidence is derived from animal data [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any of the processes associated with prerenal disease can cause ATN, but kidney damage most commonly occurs in patients with hypotension, particularly in the settings of surgery, sepsis, or obstetrical complications. The other major causes of ATN include a variety of nephrotoxins that directly damage renal tubules via a number of different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H914954245\">",
"     'Causes of ATN'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    Although renal ischemia is the most common cause of ATN, the sensitivity of individual patients to a decrease in renal perfusion is variable. In some patients, a few minutes of hypotension is sufficient to induce ATN, whereas others are able to tolerate hours of renal ischemia without structural damage to the kidney, displaying the findings of prerenal disease such as a normal urinalysis and a low fractional excretion of sodium (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Evaluation and diagnosis'",
"    </a>",
"    below). Such patients can eventually develop ATN if renal perfusion is not improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both prerenal disease and ATN can occur in a variety of settings. In addition, prerenal disease, if severe, is a common cause of ATN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914954238\">",
"    <span class=\"h2\">",
"     Causes of prerenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prerenal disease may result from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       True volume depletion",
"      </strong>",
"      &mdash; Volume depletion may be caused by gastrointestinal disease (vomiting, diarrhea, bleeding), renal losses (diuretics, glucose osmotic diuresis), skin or respiratory losses (insensible losses, sweat, burns), and third space sequestration (crush injury or skeletal fracture). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link&amp;anchor=H2#H2\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypotension",
"      </strong>",
"      &mdash; Severely decreased blood pressure can result from shock (hypovolemic, myocardial, or septic) and posttreatment of severe hypertension.",
"     </li>",
"     <li>",
"      <strong>",
"       Edematous states",
"      </strong>",
"      &mdash; Heart failure and cirrhosis can result in marked reductions in kidney perfusion that parallel the severity of the underlying disease. The respective mechanisms are decreased cardiac output in heart failure and splanchnic venous pooling and systemic vasodilation in cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=see_link\">",
"       \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H2#H2\">",
"       \"Hepatorenal syndrome\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Nephrotic syndrome, mostly in adults with minimal change disease, can also lead to AKI. Decreased renal perfusion, reduced glomerular permeability, and excessive diuresis are among the mechanisms that may contribute to AKI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18598?source=see_link&amp;anchor=H3#H3\">",
"       \"Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Selective renal ischemia",
"      </strong>",
"      &mdash; Bilateral renal artery stenosis or unilateral stenosis in a solitary functioning kidney is frequently made worse by treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, or direct renal inhibitors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link&amp;anchor=H5#H5\">",
"       \"Renal effects of ACE inhibitors in hypertension\", section on 'Renovascular hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Drugs affecting glomerular hemodynamics",
"      </strong>",
"      &mdash; Drugs that affect glomerular hemodynamics can reduce the glomerular filtration rate by lowering the intraglomerular pressure that drives this process. This can occur by decreasing either afferent (preglomerular) arteriolar dilatation (eg, with nonsteroidal antiinflammatory drugs or calcineurin inhibitors) or efferent (postglomerular) arteriolar constriction (eg, with angiotensin converting enzyme inhibitors or angiotensin II blockers).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of nonsteroidal antiinflammatory drugs is primarily seen in patients with underlying renal hypoperfusion due to true volume depletion, heart failure, or cirrhosis in which prostaglandin synthesis within or near the glomerulus is increased by vasoconstrictors such as angiotensin II and norepinephrine and vasodilator prostaglandins help preserve renal reperfusion and glomerular filtration. The effect of angiotensin inhibitors is also seen in these settings since angiotensin II helps maintain the intraglomerular pressure and glomerular filtration rate by increasing efferent arteriolar resistance. The mechanism with calcineurin inhibitors is less clear. The supporting data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\", section on 'Hemodynamically-mediated acute kidney injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H4#H4\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Reduction in GFR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link&amp;anchor=H2#H2\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\", section on 'Acute calcineurin inhibitor nephrotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914954245\">",
"    <span class=\"h2\">",
"     Causes of ATN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major causes of ATN: renal ischemia; sepsis; and nephrotoxins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9072430\">",
"    <span class=\"h3\">",
"     Renal ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;All causes of severe prerenal disease, particularly if accompanied by hypotension, surgery,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis, can cause postischemic (also called ischemic) ATN. For reasons that are not well understood, ATN is an",
"    <strong>",
"     unusual",
"    </strong>",
"    complication of heart failure and it is not clear if prolonged renal ischemia alone can lead to ATN in patients with cirrhosis in the absence of some other risk factor (eg, hypotension due to bleeding, or aminoglycoside therapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\", section on 'Protective effect of heart failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H9#H9\">",
"     \"Hepatorenal syndrome\", section on 'Acute tubular necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16010505\">",
"    <span class=\"h3\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis-induced ATN is often associated with prerenal factors such as decreased renal perfusion and systemic hypotension. Other factors can also contribute, including release of cytokines and activation of neutrophils by cytokines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\", section on 'Sepsis'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9072482\">",
"    <span class=\"h3\">",
"     Nephrotoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs and exogenous and endogenous toxins can cause ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/11\">",
"     11",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aminoglycosides (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"       \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Heme pigments (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"       \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"       \"Cisplatin nephrotoxicity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Radiocontrast media (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       Pentamidine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link&amp;anchor=H31719901#H31719901\">",
"       \"Overview of kidney disease in HIV-infected patients\", section on 'Medication nephrotoxicity'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H7#H7\">",
"       \"Foscarnet: An overview\", section on 'Renal insufficiency'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=see_link&amp;anchor=H6#H6\">",
"       \"Cidofovir: An overview\", section on 'Toxicity'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intravenous immunoglobulin, mostly in products containing sucrose which is thought to be taken up by tubular cells, leading to cell swelling and tubular obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H17#H17\">",
"       \"Intravenous immune globulin: Adverse effects\", section on 'Acute kidney injury'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"      , primarily in patients treated with more than 200 to 300",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=see_link&amp;anchor=H6#H6\">",
"       \"Complications of mannitol therapy\", section on 'Acute kidney injury'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"       Hetastarch",
"      </a>",
"      (also called hydroxyethyl starch), a hyperoncotic colloid used for fluid resuscitation in intensive care units [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/15-20\">",
"       15-20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Synthetic cannabinoids (also called SPICE, K2) are a more recently described etiology of AKI [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/21,22\">",
"       21,22",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H299038#H299038\">",
"       \"Designer drugs of abuse\", section on 'Synthetic cannabinoids (Spice, K2)'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FREQUENCY OF PRERENAL DISEASE AND ATN AS A CAUSE OF ACUTE KIDNEY INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKI, as defined by the RIFLE criteria, has been observed in 9 percent of hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/23\">",
"     23",
"    </a>",
"    ], and in more than 50 percent of patients in the intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 65 to 75 percent of cases of AKI in the hospital are due to either prerenal disease or ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. A report from Madrid, for example, evaluated all 748 cases of AKI at 13 tertiary hospital centers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/26\">",
"     26",
"    </a>",
"    ]. The most frequent causes were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ATN &mdash; 45 percent",
"     </li>",
"     <li>",
"      Prerenal disease &mdash; 21 percent",
"     </li>",
"     <li>",
"      Acute on chronic renal failure &mdash; 13 percent (mostly due to ATN or prerenal disease)",
"     </li>",
"     <li>",
"      Urinary tract obstruction &mdash; 10 percent",
"     </li>",
"     <li>",
"      Glomerulonephritis or vasculitis &mdash; 4 percent",
"     </li>",
"     <li>",
"      Acute interstitial nephritis &mdash; 2 percent",
"     </li>",
"     <li>",
"      Atheroemboli &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study based upon data from the Program to Improve Care in Acute Renal Disease (PICARD) examined the etiology of AKI in 618 critically ill patients in Intensive Care Units in five medical centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/28\">",
"     28",
"    </a>",
"    ]. The most common causes were postischemic ATN (primarily due to sepsis or hypotension and accounting for 50 percent of cases), prerenal disease (hypovolemia, hemorrhage, heart failure, shock, hepatorenal syndrome), nephrotoxicity (radiocontrast media and rhabdomyolysis were the most common), cardiovascular disease (heart failure, shock), liver disease (hepatorenal syndrome), and multifactorial etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in the evaluation of patients with AKI is a careful history and physical examination. When appropriate, prerenal disease must be distinguished from postischemic ATN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26745597\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination frequently identify events",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disease processes that result in decreased tissue perfusion that can lead to prerenal disease or postischemic ATN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The history may reveal a cause of decreased tissue perfusion (eg, vomiting, diarrhea, bleeding, or sepsis). In addition, in hospitalized patients, a close examination of the clinical setting may help identify the underlying cause of AKI (eg, hypotension, sepsis, intraoperative events, aminoglycoside therapy, or the administration of radiocontrast media, particularly in patients at increased risk). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"       \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients who develop AKI in the hospital, the day of onset can be determined if the serum creatinine concentration has been measured daily. Suppose, for example, that a patient has had a stable serum creatinine concentration, which began to rise progressively on day five. In such a patient, there must have been some insult on day four (eg, hypotension, radiocontrast media) or a cumulative insult that has become clinically apparent (eg, aminoglycoside therapy). Careful perusal of the patient's chart may identify the probable cause.",
"     </li>",
"     <li>",
"      Findings on physical examination may suggest hypovolemia such as otherwise unexplained tachycardia, dry mucous membranes, decreased skin turgor, cool extremities, supine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      orthostatic hypotension, and, particularly in the elderly, sunken eyes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link&amp;anchor=H9#H9\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure and cirrhosis can result in edema, ascites, and other signs of specific organ dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H3#H3\">",
"       \"Evaluation of the patient with suspected heart failure\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal distension leading to intraabdominal hypertension and abdominal compartment syndrome may be a complication of abdominal surgery. The mechanisms responsible for decreased renal perfusion are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link&amp;anchor=H11#H11\">",
"       \"Abdominal compartment syndrome\", section on 'Renal'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26745604\">",
"    <span class=\"h2\">",
"     Distinction of prerenal disease from ATN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing ATN from prerenal disease should be considered in patients who have a suggestive history and physical examination (as described in the preceding section) and no evidence for another cause of AKI such as aminoglycoside therapy, glomerulonephritis (which is typically associated with hematuria and dysmorphic red cells (",
"    <a class=\"graphic graphic_picture graphicRef79440 \" href=\"UTD.htm?24/0/24591\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62064 \" href=\"UTD.htm?13/47/14079\">",
"     picture 2",
"    </a>",
"    ) with or without red cell casts (",
"    <a class=\"graphic graphic_picture graphicRef55778 \" href=\"UTD.htm?34/38/35424\">",
"     picture 3",
"    </a>",
"    ), and variable degrees of proteinuria), acute interstitial nephritis (which is often drug-induced and typically associated with pyuria with or without white cell casts (",
"    <a class=\"graphic graphic_picture graphicRef75211 \" href=\"UTD.htm?14/37/14943\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54319 \" href=\"UTD.htm?24/51/25393\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68147 \" href=\"UTD.htm?33/49/34591\">",
"     picture 6",
"    </a>",
"    ) or hematuria but",
"    <strong>",
"     not",
"    </strong>",
"    red cell casts), and urinary tract obstruction (which is diagnosed by imaging studies). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H93801583#H93801583\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Nephritic pattern'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Laboratory and radiographic findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three major diagnostic approaches that, in the appropriate clinical setting, are used to distinguish prerenal disease from ATN and from other causes of AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinalysis.",
"     </li>",
"     <li>",
"      Fractional excretion of sodium and, to a lesser degree, the urine sodium concentration. The fractional excretion of urea may be helpful in patients being treated with diuretics.",
"     </li>",
"     <li>",
"      Response to fluid repletion in patients who have evidence of volume depletion, which is the gold standard for the diagnosis prerenal disease. This does not apply to prerenal disease due to heart failure (cardiorenal syndrome) or cirrhosis (hepatorenal syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients have an intermediate syndrome with features of both prerenal disease and ATN. The relative contribution of ATN can be assessed by evaluating the response to fluid repletion. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Response to fluid repletion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other parameters that may be helpful in selected patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood urea nitrogen",
"      <span class=\"nowrap\">",
"       (BUN)/serum",
"      </span>",
"      creatinine ratio",
"     </li>",
"     <li>",
"      Rate of rise of serum creatinine concentration",
"     </li>",
"     <li>",
"      Urine osmolality",
"     </li>",
"     <li>",
"      Urine volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with prerenal acute AKI due to cardiorenal syndrome or abdominal compartment syndrome, definitive diagnosis should be made with cardiac functional evaluation (eg, cardiac echo, invasive hemodynamic monitoring) or transduced bladder pressure, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=see_link&amp;anchor=H2022657#H2022657\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link&amp;anchor=H15#H15\">",
"     \"Abdominal compartment syndrome\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link&amp;anchor=H20#H20\">",
"     \"Abdominal compartment syndrome\", section on 'Measurement of intraabdominal pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26746321\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinalysis with sediment examination by urine microscopy is normal or near normal in prerenal disease unless it is superimposed on another cause of renal disease. Hyaline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fine granular casts may be seen, but these are not an abnormal finding. In comparison, the classic urinalysis in ATN reveals muddy brown granular and epithelial cell casts and free renal tubular epithelial cells (",
"    <a class=\"graphic graphic_picture graphicRef56438 graphicRef65729 \" href=\"UTD.htm?19/21/19800\">",
"     picture 7A-B",
"    </a>",
"    ). Ischemic or toxic injury to the tubular epithelial cells can lead to cell sloughing into the tubular lumen due either to cell death or to defective cell-to-cell or cell-to-basement membrane adhesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the absence of these urinary findings does",
"    <strong>",
"     not",
"    </strong>",
"    exclude ATN and their presence does not always establish the diagnosis of ATN as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell sloughing and cast formation are less prominent in patients with less severe disease and nonoliguric ATN, a setting in which the urinalysis may be relatively normal [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Marked hyperbilirubinemia alone can, via an uncertain mechanism, lead to the formation of granular and epithelial cell casts in the absence of overt tubular injury [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/35\">",
"       35",
"      </a>",
"      ]. In this setting, the urinalysis does",
"      <strong>",
"       not",
"      </strong>",
"      distinguish between prerenal disease and ATN. In contrast, marked hyperbilirubinemia does not impair sodium reabsorption; thus, measurement of the fractional excretion of sodium and the urine sodium concentration remain useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of urinalysis in distinguishing between ATN and prerenal disease was examined in a study that utilized a scoring system based upon the number of granular casts and renal tubular epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/32\">",
"     32",
"    </a>",
"    ]. There were two major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a high pretest probability of ATN, the presence of any number of casts or renal tubular epithelial cells had a very high positive predictive value and low negative predictive value for a final diagnosis of ATN.",
"     </li>",
"     <li>",
"      Among patients with a low pretest probability of ATN (ie, initial diagnosis of prerenal disease), the absence of casts or renal tubular epithelial cells had a negative predictive value for ATN of 91 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26746750\">",
"    <span class=\"h3\">",
"     Fractional excretion of sodium and urine sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine sodium concentration is widely used in patients with suspected volume depletion. In the absence of a sodium-wasting state, the urine sodium concentration in hypovolemic states should be less than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and may be as low as 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in laboratories able to detect such a low level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link&amp;anchor=H780669#H780669\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Urine sodium concentration'",
"    </a>",
"    .) However, for the reasons described in the following discussion, measurement of the",
"    <strong>",
"     fractional excretion of sodium is the preferred test",
"    </strong>",
"    for distinguishing prerenal disease from ATN as the cause of AKI.",
"   </p>",
"   <p>",
"    The urine sodium concentration tends to be low in prerenal disease (less than 20",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    in an appropriate attempt to conserve sodium, and high in ATN (more than 40 to 50",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    due, in part, to impaired tubular function induced by the tubular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/29\">",
"     29",
"    </a>",
"    ]. However, frequent overlap occurs due to variations in water reabsorption, which can affect the urine sodium concentration without affecting total sodium excretion. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with prerenal disease who is highly water-avid due to increased secretion of antidiuretic hormone may have a higher than expected urine sodium concentration, despite a low rate of sodium excretion.",
"     </li>",
"     <li>",
"      Conversely, decreased water reabsorption in ATN due to impaired concentrating ability can lower the urine sodium concentration by dilution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The FENa, which includes the urine sodium concentration, is the better test in patients with AKI since it only measures sodium handling (the fraction of the filtered sodium load that is excreted). It is not affected by changes in urine output since the urine volume is",
"    <strong>",
"     not",
"    </strong>",
"    included in the formula.",
"   </p>",
"   <p>",
"    The filtered sodium load can be determined from the product of the glomerular filtration rate (as estimated from the creatinine clearance) and the serum sodium concentration (SNa). Sodium excretion is equal to the product of the urine sodium concentration (UNa) and the urine volume (V). Thus:",
"   </p>",
"   <p>",
"    UNa&nbsp;&nbsp; x&nbsp;&nbsp; V",
"   </p>",
"   <p>",
"    FENa, percent&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp;&nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&nbsp;&nbsp;&nbsp; x&nbsp;&nbsp;&nbsp; 100",
"   </p>",
"   <p>",
"    SNa&nbsp;&nbsp; x&nbsp;&nbsp; [(UCr &nbsp;x&nbsp; V)&nbsp; &divide;&nbsp; SCr]",
"   </p>",
"   <p>",
"    Where UNa and SNa are the urine and serum sodium concentrations, UCr and SCr are the urine and serum creatinine concentrations, and [(UCr&nbsp; x&nbsp; V)&nbsp; &divide;&nbsp; SCr] represents the creatinine clearance. This equation can be simplified since the urine flow rate (V) terms cancel out, allowing the FENa to be estimated from simultaneously obtained serum and urine specimens without measuring the urine volume [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    UNa&nbsp;&nbsp; x&nbsp;&nbsp; SCr",
"   </p>",
"   <p>",
"    FENa, percent&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&nbsp;&nbsp;&nbsp; x&nbsp;&nbsp;&nbsp; 100",
"   </p>",
"   <p>",
"    SNa&nbsp;&nbsp; x&nbsp;&nbsp; UCr",
"   </p>",
"   <p>",
"    Calculators for the FENa are available using either standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or SI units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among patients with AKI, the FENa is typically less than 1 percent in prerenal disease (indicative of sodium retention) and above 2 percent in ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/36\">",
"     36",
"    </a>",
"    ]. There are conditions in which this distinction is not accurate, such as ATN superimposed upon a chronic prerenal state such as cirrhosis, a setting in which the FENa may remain below 1 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H3#H3\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'FENa in acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48984633\">",
"    <span class=\"h4\">",
"     Limitations of FENa",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several limitations to the use of FENa in distinguishing prerenal disease from ATN as the cause of AKI. This issue is discussed in detail elsewhere but a few examples will be provided here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H5#H5\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'Limitations of FENa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FENa may remain below 1 percent when ATN is superimposed upon a chronic prerenal disease such as cirrhosis or heart failure, or in a minority of patients with nonoliguric postischemic (ischemic) ATN who may have persistent renal ischemia and less severe ATN.",
"     </li>",
"     <li>",
"      A FENa below 1 percent is not unique to prerenal disease, since it can occur with other causes of AKI that are associated with a low GFR and relatively intact tubular function. These include acute glomerulonephritis, vasculitis, and contrast-induced nephropathy.",
"     </li>",
"     <li>",
"      Patients with AKI are often treated with diuretics which, if effective, can raise the FENa, even in patients with prerenal disease. Potential alternative in such patients, which have been less well studied than FENa, include the fractional excretion of molecules such as urea,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , and uric acid that are primarily reabsorbed and, with uric acid, secreted in the proximal tubule, which is proximal to the sites of action of loop diuretics (loop of Henle) or thiazide diuretics (distal tubule). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H7#H7\">",
"       \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'Fractional excretion of other molecules'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The FENa defining sodium retention",
"      <strong>",
"       varies with the filtered sodium load",
"      </strong>",
"      : below 1 percent when the filtered sodium load is low due to the marked reduction in glomerular filtration rate (GFR) in AKI; and progressively lower as the filtered sodium load increases, reaching a value of",
"      <strong>",
"       less than 0.1 percent",
"      </strong>",
"      when the GFR is normal. If, for example, the normal GFR is 180",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      (125",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      and the normal plasma water sodium concentration is 150",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      then the daily filtered sodium load will be 27,000",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      In a patient with prerenal disease, urine sodium excretion can be reduced to less than 27",
"      <span class=\"nowrap\">",
"       meq/day,",
"      </span>",
"      which represents a FENa below 0.1 percent if a normal GFR is maintained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Response to fluid repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for the distinction between prerenal disease secondary to volume depletion and postischemic or nephrotoxic ATN is the",
"    <strong>",
"     response to fluid repletion",
"    </strong>",
"    . If sufficient fluid is given to reverse any signs of volume depletion (eg, hypotension, cool extremities, low FENa and urine sodium concentration), return of the serum creatinine to the previous baseline within 24 to 72 hours is considered to represent correction of prerenal disease, whereas persistent AKI is considered to represent ATN.",
"   </p>",
"   <p>",
"    Although prerenal disease and postischemic ATN are usually discrete entities, some patients have an intermediate presentation with overlap between features of both prerenal disease (eg, low fractional excretion of sodium) and ATN, such as coarse granular casts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal tubular epithelial cells on urine microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/32,33,37\">",
"     32,33,37",
"    </a>",
"    ] and urinary biomarkers of renal tubular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26746321\">",
"     'Urinalysis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26746848\">",
"     'Investigational biomarkers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to the prompt recovery to baseline kidney function following volume repletion in pure prerenal disease, patients with prerenal disease who also have renal features of ATN may have delayed recovery to baseline kidney function after fluid repletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/37\">",
"     37",
"    </a>",
"    ]. This may reflect a pattern of patchy tubular injury (accounting for the urine manifestations and delayed recovery) interspersed among normal functioning nephrons [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unless contraindicated, a trial of intravenous fluid therapy is warranted in patients with a clinical history consistent with fluid loss (such as vomiting, diarrhea, or bleeding), and a physical examination consistent with hypovolemia (such as otherwise unexplained tachycardia, decreased skin turgor, cool extremities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supine or orthostatic hypotension). In contrast, fluid administration is",
"    <strong>",
"     not",
"    </strong>",
"    warranted and may be harmful (eg, fluid overload and pulmonary congestion) in critically ill patients with AKI who do not have a history or physical or laboratory findings suggestive of hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluid infusion to reverse prerenal disease is generally",
"    <strong>",
"     not performed",
"    </strong>",
"    in patients with obvious volume overload as in heart failure or cirrhosis, particularly in patients with pulmonary vascular congestion. However, there are some settings in which fluid repletion may be considered, particularly in patients with cirrhosis and ascites who do",
"    <strong>",
"     not",
"    </strong>",
"    have peripheral edema. In the presence of peripheral edema, the edema fluid can be rapidly mobilized with fluid loss (as with diuretic therapy), which will minimize the degree of intravascular volume depletion (",
"    <a class=\"graphic graphic_figure graphicRef70893 \" href=\"UTD.htm?10/29/10717\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/41\">",
"     41",
"    </a>",
"    ]. In contrast, in patients with ascites but",
"    <strong>",
"     no edema",
"    </strong>",
"    , the ascites fluid can only be slowly mobilized (300 to 500",
"    <span class=\"nowrap\">",
"     mL/day).",
"    </span>",
"    Thus, fluid loss as with excessive diuretic therapy, can lead to plasma volume depletion (",
"    <a class=\"graphic graphic_figure graphicRef70893 \" href=\"UTD.htm?10/29/10717\">",
"     figure 1",
"    </a>",
"    ) and elevations in blood urea nitrogen and serum creatinine. The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Overly rapid fluid removal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid repletion is typically initiated with intravenous isotonic saline. The rate of fluid repletion varies with the severity of the hypovolemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe hypovolemia or hypovolemic shock are typically treated with an initial infusion of",
"      <strong>",
"       one to two liters of isotonic saline given as rapidly as possible",
"      </strong>",
"      . The rate of further fluid repletion is governed by the blood pressure response and other clinical signs such as peripheral perfusion, mental status, and urine output. Patients with persistent hypotension are continued at the initial rapid rate as long as there are no signs of volume overload or some other cause of hypotension (eg, sepsis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Rate of fluid repletion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with mild to moderate hypovolemia are treated with isotonic saline at a slower rate. The goal of therapy, volume repletion, requires that the rate of fluid administration be greater than the rate of ongoing fluid losses. One regimen that has been used is a fluid administration rate that is",
"      <strong>",
"       50 to 100",
"       <span class=\"nowrap\">",
"        mL/h",
"       </span>",
"       above ongoing fluid losses",
"      </strong>",
"      . These include insensible losses (usually 30 to 50",
"      <span class=\"nowrap\">",
"       mL/h)",
"      </span>",
"      plus any other fluid losses (eg, gastrointestinal losses). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link&amp;anchor=H8#H8\">",
"       \"Maintenance and replacement fluid therapy in adults\", section on 'Replacement fluid therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choice of replacement fluid may be influenced by concurrent abnormalities in serum sodium or potassium or the presence of metabolic acidosis. Potassium or bicarbonate may be added in patients who have hypokalemia or metabolic acidosis, respectively, while patients who are hypernatremic may be treated with one-half to one-quarter isotonic saline at two to four times the rate of isotonic saline therapy, respectively, to achieve the same degree of sodium repletion while also treating the hypernatremia. The choice of initial replacement fluid in hypernatremic patients is dependent upon the degree of hypernatremia. Careful monitoring of the rate of correction of the hypernatremia is important with the composition",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the rate of administration of the replacement fluid being adjusted accordingly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820122#H3820122\">",
"       \"Clinical manifestations and treatment of hypokalemia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H15#H15\">",
"       \"Approach to the adult with metabolic acidosis\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"       \"Bicarbonate therapy in lactic acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link\">",
"       \"Treatment of hypernatremia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following responses to fluid repletion are compatible with prerenal disease: restoration of adequate urine flow, improvement in renal function, and a rise in urine sodium concentration which, if it is an isolated finding, can also reflect progression of prerenal disease to ATN. If the urine output does not increase and renal function fails to improve with the restoration of intravascular volume and prerenal disease is still suspected, invasive monitoring may be required to adequately assess the patient's volume status and help guide further therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link&amp;anchor=H8#H8\">",
"     \"Maintenance and replacement fluid therapy in adults\", section on 'Replacement fluid therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26746798\">",
"    <span class=\"h3\">",
"     Other tests that may be helpful",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Blood urea nitrogen/serum creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood urea nitrogen",
"    <span class=\"nowrap\">",
"     (BUN)/serum",
"    </span>",
"    creatinine ratio is normal at 10 to 15:1 in ATN (measured in",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    but is often greater than 20:1 in prerenal disease due to the increase in the passive reabsorption of urea that follows the enhanced proximal reabsorption of sodium and water [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, a high ratio is suggestive of prerenal disease as long as some other cause of a high ratio is not present. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The BUN will rise out of proportion to the serum creatinine when urea production is increased due to gastrointestinal bleeding (upper somewhat more than lower [",
"      <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/42\">",
"       42",
"      </a>",
"      ]), tissue breakdown, or glucocorticoid therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link&amp;anchor=H24#H24\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Elevation of the BUN and serum creatinine concentration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       BUN/serum",
"      </span>",
"      creatinine ratio can exceed 20:1 when loss of muscle mass in a chronically ill or elderly patient lowers creatinine production and therefore the serum creatinine concentration, independent of the glomerular filtration rate. However, this problem is chronic and cannot explain an acute rise in the BUN out of proportion to any change in the serum creatinine concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the potential utility of a high",
"    <span class=\"nowrap\">",
"     BUN/serum",
"    </span>",
"    creatinine ratio, a normal ratio is of",
"    <strong>",
"     limited",
"    </strong>",
"    diagnostic utility. In particular, prerenal disease should not be excluded by a normal ratio, since diminished urea production (due to decreased protein intake or underlying liver disease) can prevent the expected rise in BUN due to increased tubular reabsorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Rate of rise of serum creatinine concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum creatinine concentration tends to rise progressively and usually at daily a rate greater than 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (26 to 44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    per day in patients with ATN. A slower rate of rise with periodic downward fluctuations (due to variations in renal perfusion) is suggestive of prerenal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Urine osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of concentrating ability is an early and almost universal finding in ATN with the urine osmolality being below 450",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in almost all cases and usually below 350",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, a urine osmolality above 500",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    is highly suggestive of prerenal disease, since it reflects both the hypovolemic stimulus to the secretion of antidiuretic hormone and the maintenance of normal tubular function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/54/12138/abstract/29\">",
"     29",
"    </a>",
"    ]. However, lower values similar to those in ATN may be seen in prerenal disease and are therefore of little diagnostic help.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Urine volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine volume is typically, but not always, low (oliguria) in prerenal disease due to appropriate increases in both sodium and water reabsorption, which limits further fluid loss.",
"    <strong>",
"    </strong>",
"    One exception is effective diuretic therapy, which will acutely raise the urine volume while the diuretic is acting",
"    <strong>",
"     .",
"    </strong>",
"   </p>",
"   <p>",
"    In comparison, patients with ATN may be either oliguric or nonoliguric. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=see_link\">",
"     \"Nonoliguric versus oliguric acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26746848\">",
"    <span class=\"h4\">",
"     Investigational biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although measurement of the serum creatinine concentration is widely used for the detection of AKI, it does not permit early diagnosis of ATN since tubular injury precedes a significant rise in serum creatinine. Investigational biomarkers have been evaluated in patients with possible ATN in an attempt to detect tubular injury at an earlier stage. None have been approved for clinical use in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34839?source=see_link\">",
"     \"Investigational biomarkers and the evaluation of acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Limitations with underlying renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the above criteria for the diagnosis of prerenal disease may be present in a patient with underlying renal disease. In this setting, the ability to conserve sodium and the ability to concentrate the urine are often impaired and the urinalysis may be abnormal, reflecting the primary disorder. As a result, a cautious trial of fluids may be given (independent of the urinary findings) if it is suspected from the history and physical examination that an acute rise in the serum creatinine concentration may be due to volume depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two major causes of acute kidney injury (AKI) developing in the hospital are prerenal disease and acute tubular necrosis (ATN). Decreased kidney function due to prerenal disease occurs when renal ischemia is part of a generalized decrease in tissue perfusion and when there is selective renal ischemia. ATN can occur with prolonged",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe ischemia. This can result in histologic changes, including necrosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both prerenal disease and ATN can occur in a variety of settings. Prerenal disease may result from true volume depletion, hypotension, edematous states, and selective renal ischemia, while ATN is principally due to all the causes of severe prerenal disease, particularly hypotension, sepsis, and nephrotoxins. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and physical examination can frequently identify events",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      disease processes that underlie prerenal disease or ATN, suggesting the underlying diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to a careful history and physical examination, the initial evaluation to distinguish ATN from prerenal disease includes a number of laboratory measurements, close examination of the urine, and (if not contraindicated) fluid repletion. The principal diagnostic measures are urinalysis, response to fluid repletion, and fractional excretion of sodium (FENa). These three measures are used in combination with the clinical setting to help diagnose the underlying disorder. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The urinalysis is normal or near normal in prerenal disease; hyaline casts may be seen, but these are not an abnormal finding. In comparison, the classic urinalysis in ATN reveals muddy brown granular and epithelial cell casts and free epithelial cells. However, the absence of these urinary findings does not exclude ATN. (See",
"      <a class=\"local\" href=\"#H26746321\">",
"       'Urinalysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient with a clinical history consistent with fluid loss, a physical examination consistent with hypovolemia (hypotension and tachycardia)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oliguria should be administered intravenous fluid therapy, unless contraindicated. This fluid challenge attempts to correct the fluid deficit and optimize renal blood perfusion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Response to fluid repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The FENa is typically less than 1 percent in prerenal disease (indicative of the sodium retention) and above 2 percent in ATN. There are conditions in which this distinction is not accurate, such as ATN superimposed upon a chronic prerenal state such as cirrhosis, a setting in which the FENa may remain below 1 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"       \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The serum creatinine is widely used in diagnosing the presence of AKI. However, since it is a suboptimal biomarker for this process, different urinary and serum proteins have been intensively investigated. Although there are promising candidate biomarkers, none are currently approved for use clinically in the U.S. (See",
"      <a class=\"local\" href=\"#H26746848\">",
"       'Investigational biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/1\">",
"      Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract 2012; 120:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/2\">",
"      Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/3\">",
"      Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int 2007; 72:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/4\">",
"      Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/5\">",
"      Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/6\">",
"      Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/7\">",
"      Liangos O, Wald R, O'Bell JW, et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006; 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD. Pathophysiology of renal disease. 2nd Edition. 1987, McGraw Hill, New York, New York.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/9\">",
"      Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure. Kidney Int 2006; 69:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/10\">",
"      Wan L, Langenberg C, Bellomo R, May CN. Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009; 13:R190.",
"     </a>",
"    </li>",
"    <li>",
"     Rosner, MH, and Okusa, MD. Drug-associated acute renal failure in the intensive care unit. In: Clinical Nephrotoxins - Renal Injury from Drugs and Chemicals, 3rd ed, Marc E. De Broe, George A. Porter, William M. Bennett and Gilbert Deray (Ed), Kluwer Academic Press, Boston 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/12\">",
"      Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/13\">",
"      Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/14\">",
"      Pavie J, Scemla A, Bouldouyre MA, et al. Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy. AIDS Patient Care STDS 2011; 25:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/15\">",
"      Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/16\">",
"      Wiedermann CJ, Dunzendorfer S, Gaioni LU, et al. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 2010; 14:R191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/17\">",
"      Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/18\">",
"      Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/19\">",
"      Myburgh JA, Finfer S, Billot L, CHEST Investigators. Hydroxyethyl starch or saline in intensive care. N Engl J Med 2013; 368:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/20\">",
"      Boussekey N, Darmon R, Langlois J, et al. Resuscitation with low volume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kidney injury. Crit Care 2010; 14:R40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/21\">",
"      Bhanushali GK, Jain G, Fatima H, et al. AKI Associated with Synthetic Cannabinoids: A Case Series. Clin J Am Soc Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/23\">",
"      Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/24\">",
"      Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006; 10:R73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/25\">",
"      Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/26\">",
"      Lia&ntilde;o F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 1996; 50:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/27\">",
"      Nolan CR, Anderson RJ. Hospital-acquired acute renal failure. J Am Soc Nephrol 1998; 9:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/28\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 2004; 66:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/29\">",
"      Miller TR, Anderson RJ, Linas SL, et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med 1978; 89:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/30\">",
"      Espinel CH, Gregory AW. Differential diagnosis of acute renal failure. Clin Nephrol 1980; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/31\">",
"      Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002; 137:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/32\">",
"      Perazella MA, Coca SG, Kanbay M, et al. Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 2008; 3:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/33\">",
"      Perazella MA, Coca SG, Hall IE, et al. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 2010; 5:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/34\">",
"      Dixon BS, Anderson RJ. Nonoliguric acute renal failure. Am J Kidney Dis 1985; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/35\">",
"      Eknoyan G. Letter: Renal disorders in hepatic failure. Br Med J 1974; 2:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/36\">",
"      Steiner RW. Interpreting the fractional excretion of sodium. Am J Med 1984; 77:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/37\">",
"      OLIVER J, MacDOWELL M, TRACY A. The pathogenesis of acute renal failure associated with traumatic and toxic injury; renal ischemia, nephrotoxic damage and the ischemic episode. J Clin Invest 1951; 30:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/38\">",
"      Doi K, Katagiri D, Negishi K, et al. Mild elevation of urinary biomarkers in prerenal acute kidney injury. Kidney Int 2012; 82:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/39\">",
"      Belcher JM, Parikh CR. Is it time to evolve past the prerenal azotemia versus acute tubular necrosis classification? Clin J Am Soc Nephrol 2011; 6:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/40\">",
"      Schrier RW. Fluid administration in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2010; 5:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/41\">",
"      Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/54/12138/abstract/42\">",
"      Chalasani N, Clark WS, Wilcox CM. Blood urea nitrogen to creatinine concentration in gastrointestinal bleeding: a reappraisal. Am J Gastroenterol 1997; 92:1796.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7216 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12138=[""].join("\n");
var outline_f11_54_12138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9870312\">",
"      Prerenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9870320\">",
"      Acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H914954238\">",
"      Causes of prerenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H914954245\">",
"      Causes of ATN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9072430\">",
"      - Renal ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16010505\">",
"      - Sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9072482\">",
"      - Nephrotoxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FREQUENCY OF PRERENAL DISEASE AND ATN AS A CAUSE OF ACUTE KIDNEY INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26745597\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26745604\">",
"      Distinction of prerenal disease from ATN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26746321\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26746750\">",
"      - Fractional excretion of sodium and urine sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H48984633\">",
"      Limitations of FENa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Response to fluid repletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26746798\">",
"      - Other tests that may be helpful",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Blood urea nitrogen/serum creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rate of rise of serum creatinine concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Urine osmolality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urine volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26746848\">",
"      Investigational biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Limitations with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7216|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/29/10717\" title=\"figure 1\">",
"      Rapid diuretic therapy  in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7216|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24591\" title=\"picture 1\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14079\" title=\"picture 2\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35424\" title=\"picture 3\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/37/14943\" title=\"picture 4\">",
"      Photomicrograph of urine sediment with white blood cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/51/25393\" title=\"picture 5\">",
"      White blood cell cast I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/49/34591\" title=\"picture 6\">",
"      White blood cell cast II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/63/38900\" title=\"picture 7A\">",
"      Urinary sediment in acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/15/31985\" title=\"picture 7B\">",
"      Tubular epithelial cell cast in acute tubular necrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18598?source=related_link\">",
"      Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35223?source=related_link\">",
"      Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34839?source=related_link\">",
"      Investigational biomarkers and the evaluation of acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=related_link\">",
"      Nonoliguric versus oliguric acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_54_12139="Symptoms of rotavirus infection";
var content_f11_54_12139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of symptoms and signs in children with rotavirus gastroenteritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gurwith, 1981",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rodriguez, 1987",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kovacs, 1987",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dehydration",
"       </td>",
"       <td>",
"        Not stated",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory symptoms",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Reported as percentages.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12139=[""].join("\n");
var outline_f11_54_12139=null;
var title_f11_54_12140="Intraarticular steroid Indix";
var content_f11_54_12140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications and relative contraindications for intraarticular corticosteroid injection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Indications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis, persistent activity in large- or medium-sized joints in which injection may slow erosion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other inflammatory arthritides erosive or not, but particularly if oligoarticular, eg, Reiters, gout, psoriatic arthritis, other spondyloarthropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteoarthritis of large weightbearing joint (knee) with bone on bone pain and eventual total joint arthroplasty planned or accepted already",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Small joint osteoarthritis, eg, of the first carpometacarpal, especially with slight inflammatory component on physical exam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subdeltoid bursitis or rotator cuff tendonitis, first presentation or already investigated radiologically",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Relative contraindications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis in small joints of hand in which soft tissue support is necessary to prevent deformity is subject to atrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis, one joint out of proportion to others; infection suspect, culture on first athrocentesis before injection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other monoarthritis suspected of sepsis, especially in diabetes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Early osteoarthritis in which cartilage repair may be important",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Small joint osteoarthritis which failed to respond for six weeks to previous injection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subacute shoulder pain not responsive to previous injection",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12140=[""].join("\n");
var outline_f11_54_12140=null;
var title_f11_54_12141="Routine PN preterm infant";
var content_f11_54_12141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition of routine parenteral nutrition (PN) regimen for premature infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Component",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration/additive",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        12.5 percent",
"       </td>",
"       <td>",
"        Glucose = 16 g/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amino acids*",
"       </td>",
"       <td>",
"        2.6 percent",
"       </td>",
"       <td>",
"        Amino acids = 3.5 g/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cysteine-HCl",
"       </td>",
"       <td>",
"        30 mg/g amino acids",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NaCl",
"       </td>",
"       <td>",
"        2.6 mmol = 2.6 mEq",
"       </td>",
"       <td>",
"        Na = 3.4 mmol/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KCl",
"       </td>",
"       <td>",
"        0 to 0.2 mmol (mEq)",
"       </td>",
"       <td>",
"        Total K = 3.1 to 3.8 mmol/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        K",
"        <sub>",
"         2",
"        </sub>",
"        PO",
"        <sub>",
"         4",
"        </sub>",
"        -KHPO",
"        <sub>",
"         4",
"        </sub>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 to 2.0 mmol P",
"       </td>",
"       <td>",
"        P = 2.0 to 2.6 mmol/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ca gluconate",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 to 2.0 mmol Ca",
"       </td>",
"       <td>",
"        Ca = 2.0 to 2.6 mmol/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MgSO",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        0.25 mmol = 0.5 mEq",
"       </td>",
"       <td>",
"        Mg = 0.3 mmol/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multivitamin-Pediatric&reg;",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        40 percent of vial (2 mL/kg/day)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MTE-4&reg;",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        0.2 mL/kg/day",
"       </td>",
"       <td>",
"        See below for Zn, Cu, Mn, Cr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"       <td>",
"        200 mcg/kg/day",
"       </td>",
"       <td>",
"        See total zinc below",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selenium",
"       </td>",
"       <td>",
"        2 mcg/kg/day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heparin",
"       </td>",
"       <td>",
"        1 unit/mL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Intralipid&reg; 20 percent",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mL/kg/day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total fluid",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         150 mL/kg/day",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Routine use in premature infants generally after five days of age who had received the early PN regimen.",
"    <div class=\"footnotes\">",
"     * TrophAmine&reg; (B. Braun).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Monobasic-dibasic phosphate contains 1.4 mmol K/mmol P or 1.3 mmol Na/mmol P, depending upon the preparation used. Use the higher P concentration for PN duration &gt;2 weeks.",
"     <br/>",
"     &Delta; Use the higher concentration for PN duration &gt;2 weeks. Add last in the preparation of PN.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Multivitamin-Pediatric, Mayne Pharma (USA), Inc., Paramus, NJ.",
"     <br/>",
"     &sect; MTE-4, American Regent, Inc., Shirley, NY, provides:",
"     <br/>",
"     - Zn = 200 mcg/kg/day.",
"     <br/>",
"     - Cu = 20 mcg/kg/day.",
"     <br/>",
"     - Mn = 1 mcg/kg/day.",
"     <br/>",
"     - Cr = 0.4 mcg/kg/day.",
"     <br/>",
"     Total zinc = 200 + 200 = 400 mcg/kg/day.",
"     <br/>",
"     Usually begin MTE after two weeks; only Zn (400 mcg/kg/day) is needed prior to that time.",
"     <br/>",
"     &yen; Begin lipid at 1 g/kg/day and increase stepwise to 3 to 4 g/kg/day.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schanler RJ. The low birth weight infant: Perinatal nutrition. In: Nutrition in Pediatrics: Basic Science and Clinical Applications, Walker WA, Watkins JB (Eds), B.C. Decker Inc., Hamilton, Ontario, Canada 1996. Copyright &copy;1996 PMPH-USA, Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12141=[""].join("\n");
var outline_f11_54_12141=null;
var title_f11_54_12142="Cesarean delivery by age";
var content_f11_54_12142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cesarean delivery rates by age of mother: United States, 1990-2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 275px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on preliminary data.",
"    </div>",
"    <div class=\"reference\">",
"     Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary data for 2005. Health E-Stats. Released November 21, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12142=[""].join("\n");
var outline_f11_54_12142=null;
var title_f11_54_12143="Micro P marneffei yeasts";
var content_f11_54_12143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microscopic examination of",
"    <em>",
"     Penicillium marneffei",
"    </em>",
"    yeasts after incubating at 37&deg;C on brain heart infusion agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_54_12143=[""].join("\n");
var outline_f11_54_12143=null;
